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Tuberculosis (TB) is one of the most life-threatening infectious diseases in the world, 
claiming millions of lives annually. Lack of point-of-care (PoC) diagnostic tools for TB 
hinders control of the disease, particularly in resource-limited, high HIV and TB 
prevalence countries. Therefore, there is a need for simple, rapid, accurate, and 
affordable PoC diagnostics to detect active TB early enough for opportune intervention. 
To develop TB detection probes that will constitute such diagnostics, our research group 
recently isolated DNA aptamers that bind to a putative marker for active TB; the ESAT-
6.CFP-10 heterodimer. Aptamers are highly specific artificial mimics of antibodies that 
have shown great prospects in diagnostic applications. The aim of this study was to 
characterise the anti-ESAT-6.CFP-10 aptamers, and to optimise them into more specific 
and affordable detection probes for the development of potential PoC TB diagnostic 
tools. Characterisation included determining the binding kinetics of six full length (90-
mer) anti-ESAT-6.CFP-10 aptamers by Surface Plasmon Resonance (SPR) technology, 
and the analysis of the secondary structures and associated energetics using in silico 
methods. Five of the full length anti-ESAT-6.CFP-10 aptamers exhibited high affinity to 
the recombinant CFP-10 monomer, with dissociation constant (KD) values within the 
nanomolar range. In silico secondary structure analyses provided a theoretical 
framework for the target-binding motifs of the aptamer sequences. Optimisation of two 
of these aptamers, namely CSIR 2.11 and CSIR 2.19, was carried out by the rational 
truncation of the full length sequences, retaining their predicted minimum target-binding 
motifs. Rational truncation yielded two shorter derivatives of each aptamer; 70-mer and 
77-mer for CSIR 2.11, and 77-and 49-mer for CSIR 2.19. In silico conformational 
energy landscape analyses suggested that the truncated aptamers had improved folding 
kinetics compared to the full length parent aptamers. When evaluated in an enzyme 
linked oligonucleotide assay (ELONA), the functional performance of the truncated 
aptamers was comparable to that of the full length aptamers. These data suggest the 
potential utility of the truncated aptamers as candidate TB detection probes for the 
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1.1 The Epidemiology of Tuberculosis 
Tuberculosis (TB) remains a major global health burden associated with high rates of 
morbidity and mortality. There are approximately 8.7 million new cases of clinically 
active TB, and about 1.4 million TB-attributed deaths annually (WHO, 2012). Of the 8.7 
million new active TB cases, 13% were coinfected with human immunodeficiency virus 
(HIV) (WHO, 2012) . Furthermore, of the reported global 1.4 million deaths in 2011, 
almost a million were among HIV-negative individuals and 430 000 among those 
infected HIV (WHO, 2012). Globally, TB ranks as the second leading infectious disease 
(after HIV) that causes death; with the gravest burden experienced by Asia and Africa 
(WHO, 2012). This is despite the disease being largely curable and the progressive 
improvements in access to TB treatment in the last decade. 
1.2 The Pathogenesis of TB 
TB is an air-borne infectious disease caused by a group of closely related species which 
collectively form the Mycobacterium tuberculosis complex. These species include M. 
tuberculosis, M. bovis, M. africanum, M. microti, and M. canettii (Fukuda et al., 2013). 
M. tuberculosis (MTB) is the primary causative agent for the majority of human TB 
cases worldwide (Fukuda et al., 2013). This aerobic, slow-growing, rod-shaped, acid-
fast bacterium (Dinic et al., 2013) has a complex cell wall structure; which is known to 
play a role in both its pathogenesis and resistance to treatment (Knechel, 2009).  To 
elicit pathogenesis, MTB enters the airways of exposed individuals in aerosol droplets 
generated through coughing, sneezing and talking (Knechel, 2009)The introduction of 
MTB bacilli into the lungs can cause respiratory infection called pulmonary TB, which 
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Generally, a small proportion of people infected with MTB will progress to develop 
active TB disease (Smith, 2003). Most healthy individuals successfully control the 
infection through host immune response mechanisms involving the phagocytotic arrest 
of the MTB bacilli in granulomas (Smith, 2003). Successful arrest of the infection 
results in the asymptomatic and non-transmissible state of the disease, termed latent 
infection (Smith, 2003). However, if the exposed individual has compromised immunity 
as would be the case in HIV-infected persons, or immature immunity such as in children 
younger than 5 years, the infection may progress to active TB disease (Knechel, 2009, 
Smith, 2003). Furthermore, reactivation of the disease , termed secondary progressive 
TB, may occur in immunocompetent individuals within the first 2 years of initial 
infection or even decades later, under immunity-stressful conditions (Fukuda et al., 
2013). 
1.3 The problem of TB diagnosis 
Central to the burden of TB is poor diagnostics, particularly in high prevalence countries 
(Chamie et al., Dorman, 2010, Mathebula et al., 2009, Storla et al., 2008).  Delayed or 
poor diagnosis may lead to continued transmission of the disease in communities and 
hospitals (Chamie et al., Dorman, 2010). In addition, inadequacies in TB diagnostic 
tools may lead to false positives, resulting in unnecessary utilization of public health 
resources and possibly dire health consequences to patients (Chamie et al., Dorman, 
2010). 
The method most commonly used to diagnose active TB is sputum smear microscopy 
(Chamie et al., Dorman, 2010, Mayer and Dukes Hamilton, 2010, Davis et al., 2011) 
The major disadvantages of this method of detection are the requirement of laboratory 
equipment and trained personnel, as well as poor sensitivity of detection which is 
estimated at 70% but also as low as 35 % in nations with a high prevalence of HIV-TB 
coinfection (Davis et al., 2011). Some reports indicate that up to 50% of HIV-positive 
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tuberculin skin test (TST) and chest radiographs are usually used in conjunction with 
smear microscopy (Chamie et al., Dorman, 2010). However, the TST presents low 
sensitivity for active TB while chest radiography is limited to detection of pulmonary 
TB, has low sensitivity, and is generally subjective (Dorman, 2010). The diagnosis of 
extrapulmonary TB often requires invasive measures of obtaining diagnostic samples 
from the site of infection (Nicol and Zar, 2011, Parida and Kaufmann, 2010) and fairly 
technical methods of detection (Parida and Kaufmann, 2010). The culturing of MTB, 
both on solid and in liquid media, is considered the current gold standard in TB 
diagnosis and is significantly more sensitive than smear microscopy (Zeka et al., 2011). 
However, this method is time-consuming (Zeka et al., 2011), costly and also requires 
trained personnel as well as specialized Bio-safety level-3 facilities (Chamie et al., 
Dorman, 2010, Parida and Kaufmann, 2010). 
Newer technologies in TB diagnosis include the interferon γ-release assays (IGRAs) and 
nucleic acid amplification tests (NAATs). The IGRAs are serodiagnostic assays that 
offer rapid TB diagnosis based on MTB antigen-induced immune response (de Moraes 
Van-Lume, 2010, Ernst et al., 2007, Pai and Ling, 2008, Pai et al., 2008). These tests 
offer a single patient visit (de Moraes Van-Lume, 2010, Ernst et al., 2007) and modestly 
high sensitivity (de Moraes Van-Lume, 2010, Dheda et al., 2009, Ernst et al., 2007). 
However, the IGRAs have shown poor specificity as other mycobacteria (e.g. M. 
kansasii and M. marinum) can also elicit an interferon γ response, and thus a give a 
positive IGRA test (Dheda et al., 2009). One of the key shortcomings of these tests is 
the inability to distinguish active from latent TB, particularly in high burden countries 
(de Moraes Van-Lume, 2010, Dheda et al., 2009, Ernst et al., 2007). Other limitations of 
the IGRAs include the requirement of equipment and trained personnel (de Moraes Van-
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NAATs use various molecular approaches to amplify and detect the Mycobacterium 
tuberculosis complex (MTC) directly in clinical specimens, allowing for rapid and 
accurate TB detection (Antonenka et al., 2013). Commercially available NAATs used in 
TB diagnosis include the ProbeTec ET DTB (DTB)  (BD), DNA based probe 
Accuprobe (Genprobe), the Amplified M. tuberculosis Direct (AMPLIFIED MTD) test 
(GenProbe), Amplicor MTB (Roche), COBAS TaqMan MTB (CTM-MTB) (Roche), 
and the Xpert MTB/ RIF™ (Cepheid) (Boehme et al., 2010, Davis et al., 2011) . 
Although these tests offer promising potential in TB diagnosis with high specificity, 
ranging from 85–98% for smear-positive TB, they have shown poorer sensitivity (66%) 
for smear-negative TB (Nicol and Zar, 2011, Parida and Kaufmann, 2010), and still 
present some notable drawbacks particularly for PoC use (LaBarre et al., 2011). These 
tests require trained personnel, are labour-intensive and may present risk of cross-
contamination of samples (Nicol and Zar, 2011, Parida and Kaufmann, 2010). 
Furthermore, the performance of the NAATs is affected by the sample preparation, the 
extraction of DNA and the presence f PCR inhibitors (Chang et al., 2012). However, 
the fully automated Xpert MTB/RIF™ system offers an improved and easy-to-use 
NAAT alternative (Nicol and Zar, 2011, Parida and Kaufmann, 2010).  The Xpert 
MTB/RIF™ detects MTB and rifampin resistance as a surrogatee for multi-drug 
resistant (MDR) TB directly from a patient’s sputum in less than 2 hours with minimal 
risk of sample contamination (Nicol and Zar, 2011, Parida and Kaufmann, 2010). 
Moreover, the test has a sensitivity profile that is comparable to some culture methods 
but without the need for Bio-safety level 3 facilities (LaBarre et al., 2011).While the 
method presents prospects for near-patient care TB detection facilities, the high cost of 
the Xpert MTB/RIF™ system and operational challenges may be limiting factors, 
particularly in low income, TB-burdened populations (LaBarre et al., 2011). 
Collectively, the currently available TB diagnostics present drawbacks of low sensitivity 
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requirement of sophisticated instrumentation, special storage conditions and proficient 
technical workforce, and high cost implications (Chamie et al., Dorman, 2010, Ernst et 
al., 2007, Kaufmann and Parida, 2008). Apart from the shortcomings of the current 
diagnostic tools, access to TB diagnostics remains a challenge (Dorman, 2010). These 
challenges necessitate the development of an affordable; sensitive; specific; user-
friendly; rapid and robust; equipment-free and deliverable to end-users (ASSURED) TB 
diagnostic tools (LaBarre et al., 2011). In addition, these ASSURED TB diagnostic tools 
must be tailored for use in high TB and HIV prevalence developing countries (Chamie 
et al., Dorman, 2010, Ernst et al., 2007, Kaufmann and Parida, 2008).  
1.4 Surrogate TB biomarkers  and alternative tools for detection of MTB 
antigens 
1.4.1 ESAT-6 and CFP-10 are surrogate TB biomarkers 
Reliable target biomarkers are important when developing diagnostic tools (Kaufmann 
and Parida, 2008, Parida and Kaufmann, 2010). The early secreted antigenic target-6 
(ESAT-6) and culture filtrate protein-10 (CFP-10) are considered good surrogate 
biomarkers for TB detection (Andersen et al., 2000, Parida and Kaufmann, 2010).  
ESAT-6 and CFP-10 ar  secreted by the ESX-1 secretion system, which is encoded for 
by the MTB genomic region of difference one (RD1) (Andersen et al., 2000, Parida and 
Kaufmann, 2010). The RD1 is crucial in the pathogenesis of MTB, and distinguishes TB 
from non-TB-causing mycobacteria (Andersen et al., 2000, Parida and Kaufmann, 
2010). This region is deleted in all Bacillus Calmette-Guérin (BCG) vaccine strains of 
M. bovis, and is the primary deletion event responsible for attenuation of virulent M. 
bovis (Andersen et al., 2000, Parida and Kaufmann, 2010, Pym et al., 2002, Pym et al., 
2003). The RD1 region spans open reading frames Rv3871 to Rv3879c (Andersen et al., 
2000, Parida and Kaufmann, 2010). CFP-10 and ESAT-6 are encoded by Rv3874 and 
Rv3875, respectively, and are the two most predominant secretory proteins encoded by 
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is also present in M. avium, in the facultative-pathogenic M.kansasii, and the non-
pathogenic M. smegmatis. In M. smegmatis for instance, the region is proposed to play a 
role in DNA uptake (de Jonge et al., 2007), suggesting that pathogenic mycobateria have 
adapted an ancestral system for protein secretion that is necessary for survival and 
multiplication in the host cell (Andersen et al., 2000, Parida and Kaufmann, 2010). 
ESAT-6 and CFP-10 are implicated in the pathogenesis of TB (Andersen et al., 2000, 
Ernst et al., 2007, Parida and Kaufmann, 2010). While the precise role of these proteins 
is not clearly defined, they elicit cellular immune response in MTB-infected individuals 
(Andersen et al., 2000, Ernst et al., 2007, Parida and Kaufmann, 2010). Their expression 
is associated with an increase in the cytolytic ability of MTB (Lewis et al., 2003). The 
proposed pathogenesis mechanism for ESAT-6 and CFP-10 is two-fold: T-cell 
activation and macrophage deactivation (de Jonge et al., 2007). A remarkable feature of 
the CFP-10.ESAT-6 complex is the long flexible arm formed by the C-terminus of CFP-
10 (de Jonge et al., 2007). This arm is considered a contact point through which MTB 
interacts with host cell surfaces. Thus, due to their role in MTB pathogenicity and 
relatively restricted distribution in pathogenic mycobacteria, the antigenic pair may 
serve as good surrogate biomarkers for TB detection (Andersen et al., 2000, Parida and 
Kaufmann, 2010). 
For instance, the use of ESAT-6 and CFP-10 in the diagnosis of TB has been 
demonstrated; particularly in the IGRAs, the T.SPOT.TB, and QuantiFERON –TB Gold 
(QTF-G), respectively (Andersen et al., 2000, de Moraes Van-Lume, 2010, Dheda et al., 
2009, Ernst et al., 2007, Parida and Kaufmann, 2010). The IGRAs, T.SPOT.TB and 
QTF-G are serodiagnostic assays and offer rapid TB diagnosis.  These assays have been 
developed to measure the immune response to ESAT-6 and CFP-10 (Andersen et al., 
2000, de Moraes Van-Lume, 2010, Dheda et al., 2009, Ernst et al., 2007, Parida and 
Kaufmann, 2010). While these assays offer a single patient visit and modestly high 
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(Andersen et al., 2000, de Moraes Van-Lume, 2010, Dheda et al., 2009, Ernst et al., 
2007, Parida and Kaufmann, 2010). In fact, these assays are mostly effective in the 
detection of latent tuberculosis (Andersen et al., 2000, de Moraes Van-Lume, 2010, 
Dheda et al., 2009, Ernst et al., 2007, Parida and Kaufmann, 2010). 
Another example of ESAT-6.CFP-10-based TB diagnosis used monoclonal antibodies 
against the two antigens in a sandwich ELISA (Feng et al., 2011).  The performance of 
the ELISA was tested on sputum culture supernatants and pleural effusion aspirates 
(Feng et al., 2011).  The ESAT-6 monoclonal antibody-based ELISA had a sensitivity of 
95.4% and a specificity of 100% in TB samples; while the CFP-10 monoclonal 
antibody-based ELISA had a sensitivity and specificity of 81.6% and 92.2%, 
respectively (Feng et al., 2011). Furthermore, the results showed positive detection rates 
of ESAT-6 and CFP-10 of 86.8% (33/38) and 76.3% (29/38), respectively, in the 
clinical diagnosis of tuberculosis pleural effusion in patients that were negative for MTB 
culture (Feng et al., 2011). Yet, these types of antibody-based assays have drawbacks 
which hinder their use at PoC. For instance, in the current format, this ESAT-6.CFP-10 
based detection assay requires equipment and a laboratory, and highly skilled 
technicians to run and analyse the test results.  Besides, the patient samples have to be 
subjected to liquid bacterial culture prior to being tested for TB on the ESAT-6.CFP-10 
based ELISA. This approach is therefore not feasible for PoC use. Nonetheless, there are 
some commercially available rapid tests that use antibodies as detection reagents 
(Pendergrast et al., 2005). However, antibody-based tests can present drawbacks such as 
low specificity for cognate targets and the requirement of special transportation and 
storage facilities (Pendergrast et al., 2005). These limitations call for alternative 
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1.4.2 Aptamer-based sensors that detect ESAT.6.CFP-10 as alternative TB 
diagnostic tools 
Aptamer-based sensors that detect pathogenic antigens and disease biomarkers such as 
the ESAT-6.CFP-10 heterodimer are promising alternative tools for diagnosing TB. 
Aptamers are an interesting class of molecules with high specificity and sensitivity to 
their respective targets (Famulok et al., 2007, Lee et al., 2010). These molecules, which 
rival antibodies in function, are aptly defined as “chemical antibodies” (Famulok et al., 
2007, Lee et al., 2010). Aptamers have many of the functional properties and 
applications of monoclonal antibodies (Famulok et al., 2007, Lee et al., 2010). In 
addition, aptamers have advantages over antibodies; particularly in the diagnostics 
application. 
1.5 Properties and prospects of aptamers 
1.5.1 Properties of aptamers 
Aptamers are artificial nucleic acid ligands that can bind with high affinity and 
specificity to their cognate targets (Lee et al., 2008). Aptamers can in principle be 
selected against virtually any target including non-immunogenic molecules, as the 
method through which they are isolated does not require the use of living organisms 
(Strehlitz et al., 2008). Aptamers are generated from combinatorial oligonucleotide or 
peptide libraries by an in vitro  process called systematic evolution of ligands by 
exponential enrichment (SELEX) (Ellington and Szostak, 1990b). SELEX is an iterative 
process typically comprising multiple rounds of alternate cycles of ligand selection from 
pools of diverse sequences and amplification of target-binding species (Ellington and 
Szostak, 1990b). The process yields a pool of aptamer sequences that will have have 
formed specific structural compatibility interactions (secondary and tertiary) with the 
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Aptamers are typically about 22 to 100 nucleobases long, and comprise a variable region 
flanked by constant regions which allow for amplification and sequence identification 
(Ellington and Szostak, 1990b, Kanwar et al., 2011, Simmons et al., 2012). Similar to 
monoclonal antibodies, aptamers have a number of applications including biomarker 
identification (Kim et al., 2009c), therapeutics (Shigdar et al., 2011), diagnostics 
(Famulok et al., 2007, Khan, 2008, Savory et al., 2010, Zhu et al., 2010) and high 
throughput screening (Green et al., 2001). However, by virtue of their biophysical 
properties, aptamers rival antibodies in many aspects (Proske et al., 2005).  
1.5.2 Aptamers versus antibodies 
Compared to antibodies, aptamers have lower detection limits; in the low nanomolar to 
picomolar range (Chiu, 2009, Famulok et al., 2007, Pendergrast et al., 2005, Proske et 
al., 2005). Another key advantage of aptamers is their ability to fold into multiple 
intricate structures to specifically accommodate their respective targets (Proske et al., 
2005). Consequently, aptamers can be isolated against a wide range of targets, and bind 
them in a perfect manner akin to that of antibody-antigen interactions (Proske et al., 
2005). Aptamer targets include small molecules such as amino acids, chemical toxins, 
peptides, proteins, polysaccharides, and whole microorganisms such as bacteria, viruses 
and protozoa (Chiu, 2009, Famulok et al., 2007, Khan, 2008, Lee et al., 2010). 
In contrast to antibodies, aptamers are much smaller and compact; therefore bypass 
challenges such as steric hindrance when interacting with their respective targets (Chiu, 
2009, Famulok et al., 2007, Khan, 2008, Lee et al., 2010). In clinical applications, 
aptamers have faster tissue penetration and better bioavailability  (Simmons et al., 
2012). The non-immunogenic nature of aptamers also make them ideal therapeutic 
agents (Simmons et al., 2012).  Furthermore, unlike antibodies, aptamers (particularly 
DNA-based) are more stable and able to tolerate harsh chemical, physical and biological 
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after exposure to extreme conditions, which would generally be destructive to antibodies 
(Chiu, 2009, Famulok et al., 2007, Khan, 2008, Lee et al., 2010). 
In addition, aptamers have a simple conjugation chemistry, which makes them amenable 
to various chemical modifications for improved stability and the attachment of reporter 
molecules for various applications (Pendergrast et al., 2005). These properties make 
aptamers easily compatible with most biosensor devices (Famulok et al., 2007, 
Pendergrast et al., 2005, Xia et al., 2010), including multiplex systems which are able to 
detect different analytes in patients’ samples (Chiu, 2009, Famulok et al., 2007, 
Pendergrast et al., 2005). Moreover, the production of aptamers is easier and less 
expensive relative to that of antibodies (Pendergrast et al., 2005). Following initial 
isolation in vitro, aptamers can be produced in large amounts either by enzymatic 
methods or chemical synthesis (Pendergrast et al., 2005). In chemical synthesis, 
aptamers can be produced in lyophilized form without batch to batch variation, and can 
be stored at room temperature for up to a year  and retain full functionality activity 
(Pendergrast et al., 2005). 
The properties and advantages discussed above; make aptamers attractive candidate 
probe molecules for the development of highly sensitive and selective detection methods 
(Kanwar et al., 2011, Pendergrast et al., 2005). Overall, aptamer-based detection 
systems offer such advantages as rapid detection, high sensitivity and specificity, 
stability of detection probe, ease of use, relatively low cost of production, and minimal 
technical hurdles (Famulok et al., 2007, Khan, 2008, Savory et al., 2010, Zhu et al., 
2010). 
1.5.3 Aptamer-target interaction 
The term “aptamer” is derived from the Latin word aptus, meaning “to fit”, and the 
Greek word meros, meaning “part” or “region” (Ellington and Szostak, 1990b, 
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meros describes the inherent manner in which an aptamer interacts with its target. These 
interactions occur mainly via structural compatibility between the aptamer and the target 
(Kanwar et al., 2011, Pendergrast et al., 2005).  
Aptamer structures are driven by and formed through complementary base-pairing 
(Pendergrast et al., 2005). These secondary structures primarily consist of short helical 
(double-stranded) stems and single-stranded loops (Hermann and Patel, 2000). These 
stem-loop structures form the basis of aptamer-target interaction (Figure 1-1). The 
helical regions stabilise the secondary structures and allow the single-stranded regions 
(loops and such others) to “collapse” into the most likely three-dimensional shapes  that 
are suitable for target interaction (Gold et al., 2012).  
The multiple stable tertiary structures resulting from the different combinations of 
secondary structures, allow aptamers to bind to their respective targets via electrostatic 
interactions, ionic or dipole forces, Van der Waals interactions, as well as hydrogen 
bonds and stacking interactions (Hermann and Patel, 2000, Pendergrast et al., 2005). 
Sequence-specific interactions of aptamers with their respective targets are based on 
hydrogen bonds and Van der Waals interactions, while nonspecific interactions result 
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1.5.4 Applications of aptamers 
Aptamers have a wide range of applications; in basic research (Marro et al., 2005), 
biomarker discovery, in environmental analytics (Stoltenburg et al., 2012, Kim et al., 
2009a) and clinical practice (Moore et al., 2011, Ng et al., 2006, Rusconi et al., 2004). 
For basic research purposes, aptamers can be used for target validation and biomarker 
discovery (Chang et al., 2013), as well as to study the functional properties and 
mechanisms of complementary targets such as proteins and enzymes (Marro et al., 
2005). Environmental applications of aptamers include the detection and removal of 
toxic substances for such purposes as water remediation. In 2009, Kim and colleagues 
developed DNA aptamers that are able to remove arsenic from Vietnamese groundwater 
(Kim et al., 2009b). Furthermore, aptamer-based sensors can be used in the 
identification of toxins in food and agricultural products (Kim et al., 2009b). Recently, 
NeoVentures Biotechnology has successfully commercialized the first aptamer based 
diagnostic platform for analysis of mycotoxins in grain (Rusconi et al., 2004). 
Figure 1-1: Schematic illustration of aptamer-target interaction. Upon encountering a 
target, an aptamer assumes a target-induced conformation. The structural compatibility 
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In clinical practice, aptamers can be used both as detection reagents in diagnostics, and 
as active molecules in therapeutic agents (Rusconi et al., 2004). Macugen (Pegaptanip) 
is the first aptamer-based therapeutic agent to be used in clinical practice (Ng et al., 
2006).  Macugen is used to treat macular degeneration (Ng et al., 2006). The therapeutic 
is based on an RNA aptamer with both a high affinity for, and an antagonistic effect on 
the Vascular Endothelial Growth Factor (VEGF), and can thus inhibit angiogenesis (Ng 
et al., 2006). Aptamers also have potential applications in the control of infectious 
diseases such as HIV (Dey et al., 2005, Khati et al., 2003, Moore et al., 2011). 
Moreover, aptamers can be used, with suitable nanocarriers for targeted drug delivery 
(Kanwar et al., 2011). For instance, aptamers isolated against prostate  specific 
membrane antigen (PSMA) was conjugated to nanoparticles for potential targeted 
prostate cancer therapy (Ng et al., 2006).  
1.5.4.1 Aptamers in diagnostics  
In clinical diagnostics, aptamers can be used as probe molecules in a variety of 
molecular sensors for the detection of specific biomarkers (Reviewed in (Kanwar et al., 
2011). These sensors can take on a range of formats such as ELISA (Drolet et al., 1996), 
electrochemical devices (Ikebukuro et al., 2004), quartz crystal-based detectors (Liss et 
al., 2002), Surface Plasmon Resonance (SPR) technology (Proske et al., 2005, Wang et 
al., 2008, Xia et al., 2010), lateral flow strip assays (Liu et al., 2009, Liu et al., 2006), 
and simple, single step (“mix and measure”) nanoparticle solution-based detection 
systems (Proske et al., 2005, Wang et al., 2008, Xia et al., 2010). As indicated, such 
properties as size, conformational flexibility, ease of modification and high stability, 
make aptamers readily compatible with most biosensor designs.  
Both RNA and DNA aptamers can be easily conjugated to reporter molecules for use in 
biosensors, without compromising their functionality (Chiu, 2009, Famulok et al., 2007, 
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aptamers are usually preferable due to the inherent stability of DNA relative to RNA 
(Moore et al., 2011, Neves et al., 2010). Generally, DNA aptamers can be readily 
synthesized, chemically modified, refolded, and integrated into microarrays, 
microfluidics, sandwich assays and electrochemical biosensors (Neves et al., 2010). 
Examples of DNA-aptamer based biosensors include those that detect ATP (Jhaveri et 
al., 2000), thrombin (Li et al., 2002), cocaine (Stojanovic et al., 2001), PDGF (Fang et 
al., 2003),  Type 2 Diabetes biomarker (Retinol Binding Protein 4) (Lee et al., 2008) and 
avian influenza virus, H5N1 (Bai et al., 2012). 
1.5.4.1.1 Simple aptamer-based detection systems: potential design suitable for 
PoC diagnostic  
In the construction of aptamer-based biosensors, several methods have been developed 
to translate the aptamer-target binding events into physically detectable signals (Wang et 
al., 2008). These methods include functionalizing aptamers for optical or 
electrochemical sensing with fluorophores, nanoparticle labels or label-free detection 
systems (Wang et al., 2008). Gold nanoparticles (AuNPs) have been widely used to 
enable simple visual detection in diagnostics kits and immunochromatographic strips 
(Wang et al., 2008, Xia et al., 2010, Xu et al., 2009). This is due to the unique optical 
properties of AuNPs, which allow for sensitive detection of molecules from an analyte 
within minutes (Wang et al., 2008, Xia et al., 2010, Xu et al., 2009). Other beneficial 
properties of AuNPs include their long-term stability and compatibility with most 
biomolecules including antigens, antibodies, and DNA (Wang et al., 2008, Xia et al., 
2010, Xu et al., 2009).  
The use of aptamer-AuNPs conjugates for improved, highly sensitive and specific 
molecular diagnostics with low technical hurdles has been demonstrated (Chiu, 2009, 
Xia et al., 2010). Examples of aptamer-AuNP detection systems include lateral flow 
(Liu et al., 2009, Liu et al., 2006) and colloidal gold solution sensors (Chiu, 2009, Liu 
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have been shown to work for the detection of both recombinant targets in buffer and 
native forms of the target in biological fluids such as  serum (Chiu, 2009, Xia et al., 
2010). The principle of an Aptamer-AuNP “one-step” detection system is illustrated 
(Figure 1-2).  
 
Figure 1-2: Schematic illustration of a simple aptamer-AuNPs-based detection system. 
A. The principle of aptamer-AuNP-based target recognition. Aptamers are conjugated to 
AuNPs through various methods to form simple detection probes. The conjugated 
aptamer prevents aggregation of the AuNPs. The distance between the AuNPs affects 
their optical properties and colour. Upon target-binding, the aptamers are sequestered 
from the AuNPs, shortening the distance between particles and causing a change in the 
refractive index which results in colour change. B. Schematic illustration of a potential 
simple “mix and detect” Aptamer-AuNPs based detection system. Addition of the 
patient sample containing the aptamer target will change colour in the detection probe, 
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1.5.5 Aptamer characterisation: approaches for determining aptamer fitness 
for use 
There are certain criteria that aptamer-based detection probes have to meet in order to be 
incorporated into a sensing platform for biosensor design (Famulok et al., 2007). These 
criteria include high affinity and specificity for the target, as well as appropriate 
sequence length for optimal functionality (Famulok et al., 2007, Proske et al., 2005). 
Several methods have been employed in characterising aptamers on the basis of these 
criteria. Common methods include quantifying aptamer-target interactions by 
determining their binding kinetics (Murphy et al., 2003, Ruigrok et al., 2012, Win et al., 
2006), and analysing the structural properties of the aptamers to determine  the key 
features that contribute to their target-recognition function (Nonaka et al., 2010, 
Shangguan and Tang Z., 2007, Wuchty S, 1998, Zhou, 2010).  
1.5.5.1 Functional characterisation and binding affinities of aptamers  
An assay similar to ELISA is commonly used to determine binding of aptamers to their 
respective targets (Drolet et al., 1996). In this assay, termed enzyme linked 
oligonucleotide assay (ELONA), aptamers replace antibodies as target recognition 
molecules (Drolet et al., 1996). The ELONA generally works for an end-point read-out, 
providing a “yes/no” answer, suitable for high throughput screening of individual 
aptamers clones for target-recognition ability. In order to study aptamer-target 
interactions in more detail, and to determine the binding affinities or kinetics, 
technologies such as Electrophoretic Mobility Shift Assay (EMSA) and Surface 
Plasmon Resonance (SPR) can be used for semi-quantitative and quantitative analysis, 
respectively (Murphy et al., 2003, Win et al., 2006).  
EMSA can be used for the characterisation of biomolecular interactions in various 
qualitative and quantitative analyses, particularly for detecting protein-nucleic acid 
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nucleic acids are combined, and subjected to native or non-denaturing electrophoresis 
using either polyacrylamide or agarose gel (Hellman and Fried, 2007). Following 
electrophoresis, the distribution and migration patterns of the species containing nucleic 
acid throughout the gel is determined, usually by autoradiography or phosphorimaging 
(Hellman and Fried, 2007). The general principle is that during electrophoresis, the 
protein-nucleic acid complexes migrate more slowly than the corresponding free nucleic 
acids; therefore aptamer-target complexes versus free (unbound) aptamer can be 
visualized and quantified. While EMSA is traditionally used to assess binding and 
conformational characteristics of protein-DNA interactions, it can under specific 
conditions be used to determine binding stoichiometry (based on the amount of complex 
formed as a function of protein concentration at equilibrium), as well as  kinetic 
parameters such as ratio of the association and dissociation constants or (Hellman and 
Fried, 2007, Demarse et al., 2009).  
Conversely, molecular interactions between aptamers and cognate ligands can be 
studied in real-time and quantified using SPR technology (Luzi et al., 2003). SPR is a 
reference optical method which allows for the label-free detection and quantification of 
specific ligand-analyte interactions in real time (Luzi et al., 2003). The technology 
enables rapid, high-throughput screening of molecular interactions and associated 
equilibrium and kinetic binding properties (Li et al., 2006, Potyrailo et al., 1998, 
Tombelli et al., 2005, Win et al., 2006). As a result, the technology has been widely 
employed to determine interactions between a range of aptamers and their respective 
targets (Li et al., 2006, Potyrailo et al., 1998, Tombelli et al., 2005, Win et al., 2006). 
Essentially, SPR can be used to determine whether or not aptamer-target molecules 
interact, how fast or how slow they dissociate, and in some cases, if there are any 
conformational changes associated with these interactions (Luzi et al., 2003). This 
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interaction is probed in real-time, and the information required for quantifying kinetic 
parameters is easily obtained (Luzi et al., 2003). 
In a typical SPR experiment, a ligand is immobilised on a metal coated sensor chip 
surface, followed by injection of a sample solution containing the analyte at a constant 
flow rate (Win et al., 2006). The detector part of the SPR instrument then monitors and 
records the binding events as the change in the refractive index (resonance angle 
occurring at the chip surface) as a function of time (Luzi et al., 2003). This change in 
refractive index angle is proportional to the amount of bound molecules (Luzi et al., 
2003). The sensing signal is then recorded relative to the base signal, and gives an 
indication of the strength of the interaction (Luzi et al., 2003). From this output, key 
kinetic parameters such as the association (ka), dissociation (kd), and equilibrium (KD) 
constants can be derived (Luzi et al., 2003). This information then gives an idea of the 
likelihood of the aptamer-target complex to associate or dissociate reversibly into its 
composite parts (Gopinath, 2010). Overall, SPR allows for the convenient quantitative 
characterisation of aptamer-target interactions (Win et al., 2006). In addition, the high-
throughput nature of the SPR platform may be extended to screening the optimal 
truncated and modified versions of aptamers, thereby circumventing the need for the 
more time-consuming and labour-intensive chemical probing experiments and the 
occupational hazard associated with radioactive shift assays (Win et al., 2006).  
1.5.5.2 Computational characterisation of aptamer secondary structures  
In contrast to protein folding, secondary structures of nucleic acid molecules such as 
aptamers provide information that fairly represents their thermodynamics and folding 
kinetics (Wolfinger et al., 2004, Wuchty S, 1998, Michael T. Wolfinger et al., 2004). 
Consequently, secondary structures have been used as a “surrogate for function” 
(Cowperthwaite and Ellington, 2008) for nucleic acids. Likewise, secondary structures 
of aptamers can provide a level of description that adequately depicts aptamer-ligand 
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driven by structural compatibility interactions. These interactions are primarily a 
consequence of aptamer secondary structures  (Patzel, 2004). This concept is also 
demonstrated by in silico selections, which are secondary-structure-based (Hall et al., 
2007, Patzel, 2004), as well the post-SELEX analyses and optimisation of aptamer 
structures (Cowperthwaite and Ellington, 2008, Nonaka et al., 2010). 
Secondary structures of nucleic acid aptamers can be represented in a number of 
different conformations consisting of helical stems (double stranded regions—with two 
or more paired bases) and single stranded loops (Flamm  et al., 2004, Wuchty S, 1998).  
The helices are typically composed of Watson-Crick (A-U/T, T/U-A, C-G, G-C) or 
wobble (G-U, U-G) base pairs (Flamm  et al., 2004, Wuchty S, 1998). The overall 
structure can be decomposed into a collection of different configurations of these 
stacked helical stems and non-paired bases (Figure 1-3), the arrangement of which is 
specifically defined by the cognate target.  
Secondary structures of aptamers are stabilised in part by hydrogen bonds between the 
canonical bases (Flamm  et al., 2004, Wuchty S, 1998), and stacking interactions 
between the aromatic rings (Mignon et al., 2005). The stacking interactions form 
between base pairs in helical stem structures, irrespective of the actual nucleobase 
(Flamm  et al., 2004, Wuchty S, 1998). Furthermore, the overall structure of the aptamer 
is stabilised by tertiary interactions, however to a lesser extent (Ellington and Szostak, 
1990a). These tertiary interactions can include pseudo-knots, non-standard base pairings 
and base-triplets (Ellington and Szostak, 1990a, Leontis et al., 2006). Another common 
conformational arrangement that can be assumed by aptamers is the G-quadruplex. This 
is a planar conformation constituted by an array of four guanines, with each guanine 
paring two neighbours via Hoogsteen bonding (Nonaka et al., 2010, Potty, 2008). This 
conformation is known to present highly stable and robust structure and well defined 
contact points for aptamers (Nonaka et al., 2010, Potty, 2008). All these interactions 
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1999). Like any nucleic acid, the number of potential structures that an aptamer 
sequence is capable of forming (N) is hypothesised to increase in a roughly exponential 
manner as a function of length (L) (Ellington and Szostak, 1990a, Jayasena, 1999), as 
depicted by the equation: N = (1.8) L (Ellington and Szostak, 1990a, Jayasena, 1999, 
Zuker and Sankoff, 1984). 
Secondary structure folding is an energy-driven process whose goal is to achieve 
maximum complementary nucleotide base-pair stacking at the lowest possible energy 
cost (Heine et al., 2006, Wuchty S, 1998). The extent to which an aptamer secondary 
structure is able to fulfil these requirements, gives an indication of the stability of that 
particular structure (Flamm et al., 2000, Flamm  et al., 2004). During the folding 
process, each assembly of an energetically favourable helical (double-stranded) region is 
complemented with the formation of an energetically unfavourable loop (unpaired) 
region (Flamm  et al., 2004, Heine et al., 2006, Wuchty S, 1998). This tension of 
“frustrated” energetic patterns (Wuchty S, 1998) is responsible for the multiple 
variations of helix-and-loop arrangements for any individual nucleic acid sequence 
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Secondary structures provide not only the geometric skeleton, but also the 
thermodynamic and kinetic framework for the full tertiary structures of nucleic acids 
(Heine et al., 2006, Wuchty S, 1998). The folding energies of secondary structures are 
known to account for a significant portion of the overall folding energy of the full 
tertiary structures of nucleic acids (Flamm et al., 2000). Hence, examining secondary 
structures of aptamers can provide such analogous information; which will correspond 
with or describe (at least in part) the structural features of aptamers that influence their 
target-recognition ability (Heine et al., 2006, Wuchty S, 1998). 
The secondary structure folding process has to adhere to a specific set of rules. The first 
is to maximise the number of admissible or “legal” base pairs (Flamm et al., 2000). 
Figure 1-3: Schematic illustration of typical secondary structure composition of nucleic 
acid aptamers.  The structures generally consist of unfolded regions (solid lines), double 
stranded (helical) stem regions (formed by complementary nucleobase-pairing), and 
single stranded loop regions. The stem regions help stabilize the overall structure while 
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Here, the basic structural building block is an individual base pair that follows either the 
Watson-Crick or non-Watson-Crick rules outlined above (Wuchty S, 1998). The second 
obligation is to reduce the energy cost of the secondary structure by minimising its free 
energy (Flamm et al., 2000, Flamm  et al., 2004). The lower the overall free energy, the 
more stable the structure (Flamm et al., 2000, Flamm  et al., 2004). Secondary structures 
of nucleic acids, and by extension, of aptamers, can be adequately predicted using 
computational modelling methods (Aviram et al., 2012, Lorenz et al., 2011, Mathews 
and Turner, 2006, Zuker, 2003).  
Nucleic acid secondary structure and hybridisation prediction tools have been developed 
using dynamic programming algorithms (Flamm et al., 2000, Lorenz et al., 2011, Zuker, 
2003). These algorithms have been refined over the years based on desired applications; 
particularly the need to answer specific structural questions and represent respective 
biological systems more adequately. The most common of these secondary structure 
prediction tools are  mfold (Zuker, 2003), and the Vienna RNA package (reviewed in 
(Gruber et al., 2008)). These programs use standard energy models of biopolymers (e.g. 
nucleic acids) in solution (Flamm et al., 2000), which account for the thermodynamic 
parameters for several motifs typically composite of secondary structures (Wolfinger et 
al., 2004). These motifs include Watson-Crick base pairs, internal mismatches, terminal 
mismatches, terminal dangling ends, hairpins, bulges, internal loops, and multibranched 
loops (reviewed in (SantaLucia and Hicks, 2004)). The common standard energy model 
used by these prediction programs defines the overall free energy of a given nucleic acid 
secondary structure as the sum of sequence-dependent contributions for each loop 
(Flamm et al., 2000). The secondary structure modelling thereof typically results in a 
single structure which reasonably meets the above mentioned criteria for nucleic acid 
folding (i.e. legal base pairing and low free energy). The resultant structure, usually the 
one most likely to be stably assumed, is termed the minimum free energy (MFE) 
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It is well known that the folding of nucleic acids into secondary structures is not a static 
process (Flamm et al., 2000, Zuker and Sankoff, 1984). Moreover, this dynamic process 
does not always result in a single structure for any given sequence (Flamm et al., 2000, 
Zuker and Sankoff, 1984). While the MFE conformation is often the most common and 
dominant structure occurring at equilibrium (Flamm et al., 2000), it is usually not the 
only structure that can occur (Wolfinger et al., 2004, Wuchty et al., 1998). In fact, with 
the formation of the MFE for any given nucleic acid sequence, comes a subset of 
suboptimal structures with low free energies within the same range as that of the MFE 
(Wuchty et al., 1998, Zuker and Sankoff, 1984). These suboptimal structures represent 
well-defined transition steps encountered along the folding pathway that eventually 
results in the MFE (Wolfinger et al., 2004). These transitional steps are essentially 
alternative conformations to the MFE, which the nucleic acid sequence can also stably 
assume (Wolfinger et al., 2004). Hence, these alternative conformations may in some 
instances act as “kinetic traps” (Wolfinger et al., 2004) which hinder equilibration, i.e. 
prevent the folding of a sequence into a “true” and stable MFE within the typical 
lifetime of that nucleic acid molecule (Flamm et al., 2000, Heine et al., 2006, Wuchty et 
al., 1998). Furthermore, these intermediate structures can affect the biological function 
of the nucleic acid, as it is possible for alternative conformations of the same nucleic 
acid sequence to perform completely different functions (Wolfinger et al., 2004). 
Congruently, secondary structures of aptamers are defined by similar folding dynamics 
as those described above. Along the folding path from the open chain to the MFE, 
aptamers can also fold into a range of meta-stable structures, which could compete with 
the MFE and interfere with its functionality (Gruber et al., 2008, SantaLucia and Hicks, 
2004, Wolfinger et al., 2004). Essentially, aptamers can fold into target-binding 
structures that are deemed “ligand-competent”, as well as those that are “non-ligand-
competent” (Hall et al., 2007, Mathews and Turner, 2006). In the event that the former 
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Szostak, 1990a, Jayasena, 1999). This process is time-dependent; like any reaction 
proceeding towards a state of equilibrium (Hall et al., 2007, Mathews and Turner, 2006). 
This means that there is a specific time frame within which reactants (in this case 
aptamer and cognate ligand) are consumed and products (aptamer-ligand complexes) are 
formed (Hall et al., 2007, Mathews and Turner, 2006, Patzel, 2004). If the ligand is not 
bound to the aptamer within this time frame, proper aptamer folding may not occur, thus 
resulting in non-optimal aptamer function (Hall et al., 2007, Heine et al., 2006, Mathews 
and Turner, 2006, Patzel, 2004). Hence, a detailed analysis of the folding dynamics of 
aptamer secondary structures may help characterise the target-recognition fitness of 
certain aptamer structures. This type of analysis will give a more dynamic view of the 
aptamer folding process, beyond the “static” picture provided by standard energy 
minimisation methods, which only present the end-point conformation (i.e. the optimal 
(MFE) and near-optimal secondary structures). To better describe the dynamics of such 
a folding process, folding landscape modelling is used (Cowperthwaite and Ellington, 
2008). 
1.5.5.2.1 Secondary structure folding landscapes: concept and significance  
A folding landscape can be defined as a map of the folding process which provides 
information about the thermodynamics and folding kinetics of nucleic acid structures 
(Cowperthwaite and Ellington, 2008, Wolfinger et al., 2004). Thermodynamically, a 
folding landscape is defined by the ensemble of free energies of all possible 
conformations that a particular sequence can assume (Wolfinger et al., 2004). Each 
conformation is associated with both an energy value and a distance measure relative to 
all other possible conformations for that sequence (Cowperthwaite and Ellington, 2008, 
Wolfinger et al., 2004). On the other hand, folding kinetics are concerned with the 
change in molecule structure over time (Cowperthwaite and Ellington, 2008), which is 
an energy-driven process  (Flamm et al., 2000, Wuchty et al., 1998). These kinetics 
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secondary structures, and the rate of occurrence of these structures within a given time 
frame (Cowperthwaite and Ellington, 2008).  
Folding landscapes are interesting to examine as they give an indication of nucleic acid 
structural fitness and stability (Cowperthwaite and Ellington, 2008, Flamm et al., 2000). 
They provide a compact picture of the likelihood of a conversion between the MFE and 
suboptimal structures of each sequence (Cowperthwaite and Ellington, 2008). The 
“kinetic trapping” effect triggered by the suboptimal structures encountered along the 
pathway to the MFE is a consequence of the energy barriers associated with these 
structures (Flamm et al., 2000, Heine et al., 2006, Wolfinger et al., 2004). These energy 
barriers represent the amount of activation energy that is required for a sequence to 
change from one conformation to another (Heine et al., 2006).  
On the whole, folding landscapes can help determine a few key features about the 
secondary structures of aptamers. Firstly, they give an estimate measure of how long it 
takes for the system (the folding process) to reach an equilibrium state, having started 
from an open chain conformation (Flamm et al., 2000, Heine et al., 2006, Wolfinger et 
al., 2004). Secondly, they provide a visual depiction of the extent to which the 
intermediate (suboptimal) structures are being populated on the path from the initial 
structure to the MFE (Flamm et al., 2000, Heine et al., 2006, Wolfinger et al., 2004). 
Finally, folding landscapes can estimate the passage times (folding or refolding times) 
(Wolfinger et al., 2004) of specific conformations along the folding pathway. Therefore, 
analysis of folding landscapes of aptamers can help predict the structure that is most 
likely to occur without getting trapped in suboptimal intermediate conformations 
(Aviram et al., 2012, Flamm et al., 2000, Wolfinger et al., 2004). Furthermore, this 
analysis can determine how smoothly the folding occurs in time, and discriminate those 
structures that get stuck in meta-stable conformations within a given folding time 
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1.5.5.2.2 Computational estimation of folding energy landscapes 
Folding landscapes have been commonly computed using the Boltzmann probability of 
the MFE structure (Ancel and Fontana, 2000, Mathews and Turner, 2006). The 
Boltzmann probability can be defined as an approximate measure of the fraction of time 
that an aptamer sequence spends folded into a particular shape (Ancel and Fontana, 
2000). Generally, the MFE structure will likely have the largest Boltzmann probability 
of any shape an aptamer sequence may assume (Mathews and Turner, 2006). If the 
Boltzmann probability of an aptamer’s MFE is large, then the aptamer is expected to 
stably assume its MFE conformation most of the time (Ancel and Fontana, 2000). 
However, this probability can be small, in which case the aptamer is not expected to 
stably fold into its MFE shape (Ancel and Fontana, 2000).  
Computational estimation of secondary structure folding energetics and mechanics can 
indeed be made possible by efficient polynomial algorithms (Wuchty et al., 1998), and 
allow for a more detailed analysis of the folding landscape (Wolfinger et al., 2004). 
These algorithms enable the efficient prediction of the MFE structure, all possible base-
pairing probabilities, and all the suboptimal structures occurring within a given energy 
threshold from the MFE (Flamm et al., 2000, Slutsky and Mirny, 2004). Furthermore, 
these refined algorithms are able calculate the probability of the formation of a given 
structure within an ensemble of potential structures (Flamm et al., 2000, Slutsky and 
Mirny, 2004). However, it is important to note that molecular energies cannot be 
computed precisely due to the imperfect nature of the theoretical models used by  these 
algorithms (Wuchty et al., 1998), which do not account for solvation or intermolecular 
influences (Flamm et al., 2000). Although, factoring in the folding energies of a sample 
of intermediate structures (minima) within a given range above the MFE is considered 
sufficient for most folding landscape estimations (Slutsky and Mirny, 2004). 
 A smooth folding landscape is one that has fewer suboptimal structures within a given 















 27   
 
This phenomenon is called  “downhill folding” (Wolfinger et al., 2004), where there is 
little or no energy barrier, and folding into the MFE occurs relatively quickly (Heine et 
al., 2006). Conversely, “rougher landscapes” have at least one or more energy barriers 
(Wolfinger et al., 2004), which slow down transition times and adversely affect 
pathways to the MFE structure (Heine et al., 2006).  
Alternative to the complex mathematical calculations and simulations, barrier trees can 
be used to describe the folding dynamics of an aptamer (Wolfinger et al., 2004). Barrier 
trees provide a coarse-grained simplified model of an energy landscape by discarding all 
(fully) unstable structures and retaining only the meta-stable conformations along the 
folding pathway (Schuster, 2009). In the simplest case, transition rates between these 
structures are modelled and presented according to their respective energy barrier 
heights, which represent the amount of activation energy required to switch from one 
conformation to another (Flamm et al., 2000).  Barrier trees can be computed using the 
Vienna RNA Barriers Program (Flamm et al., 2000). The program makes it possible to 
sample suboptimal structures from an ensemble of possible structural motifs, and 
determine their equilibrium probability (Hofacker et al., 2010). The Barriers algorithm 
works by processing the potential conformations in an energy-sorted order (Flamm et 
al., 2000). From this “energy or cost-sorted” list of conformations, a barrier tree is 
constructed (Flamm et al., 2000),which contains either all possible conformations for a 
given sequence, or only those below a set energy threshold (Hofacker et al., 2010). 
While the model is simplistic in that it only represents transition rates between 
intermediate structures, which are represented by their respective barrier heights in the 
tree conformations (Slutsky and Mirny, 2004, , Heine et al., 2006, Wolfinger et al., 
2004), it provides sufficient information which sums up the key features of a folding 
landscape (Wolfinger et al., 2004). Taken together, the secondary structure features 
discussed above (thermodynamics and kinetics) are  worth examining in aptamer 
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aptamers and their influence on aptamer-target interactions. Furthermore, the 
bioinformatics approaches described above can be used to complement and guide 
laboratory-based experiments in the process of aptamer optimisation, and the subsequent 
design of the aptamer-based detection probes. 
1.5.6 Post-SELEX Optimisation of Aptamers  
The main prerequisites for aptamers as diagnostic probes are high affinity, selectivity to 
targets (Potty, 2008, Shangguan and Tang Z., 2007), as well as satisfactory stability in 
biological fluids (Dey et al., 2005, Savory et al., 2010, Shangguan and Tang Z., 2007). 
A key factor in aptamer-target recognition and interaction is aptamer stability, which 
depends largely on the biophysical properties of aptamers such as the sequence length 
and folding conformation (Nonaka et al., 2010, Potty, 2008). Optimisation of these 
features may result in improved aptamer functionality. 
1.5.6.1 Aptamer sequence length, contribution to function, and optimisation by 
truncation 
Full length aptamers, that is, those comprising a full random region (as evolved from the 
original SELEX library), flanked by constant regions, generally consist of two distinct 
motifs; target-binding/binding-facilitating motifs, and regions that do not participate in 
either aspect of target binding (Zhou, 2010). The elimination of the latter (i.e. non-
essential nucleotides) through the post-SELEX truncation of aptamer sequences has 
been shown in some instances, to improve the binding functionality and kinetics of 
aptamers (Nonaka et al., 2010, Savory et al., 2010, Shangguan and Tang Z., 2007, Zhou, 
2010).  
As discussed previously, an aptamer structure takes on a target-induced conformation 
with numerous discriminatory intermolecular contacts that are target-specific (Flamm et 
al., 2000, Heine et al., 2006, Wuchty et al., 1998). On this basis, Nonaka et al (2010) 
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target molecule to its specific binding pocket on the aptamer (Nonaka et al., 2010). An 
additional postulation in this regard was that reducing the length and consequently the 
overall structure of the aptamer, should make the target-binding domain of the aptamer 
more accessible, and thus improve binding affinity. Accordingly, Nonaka and 
colleagues set out to minimise the sequence of an aptamer isolated against the vascular 
endothelial growth factor (VEGF) with a view to enhance its affinity for VEGF (Nonaka 
et al., 2010). This modification resulted in retained affinity for the VEGF protein, and 
improved kinetics; from 20 nM to 1.4 nM (Nonaka et al., 2010). 
From a structural point of view, truncating the aptamer sequences may improve the 
stability of the aptamers by favouring their ligand-competent (target-biding) structures 
(Ancel and Fontana, 2000, Mathews and Turner, 2006). Shortening the sequences will 
likely reduce the number of potential structures, given that this number is said to 
increase exponentially as a function of length (Zuker and Sankoff, 1984). This may 
decrease the likelihood that the aptamer will be trapped in suboptimal conformations in 
the folding process towards the optimal target-binding shape (Ancel and Fontana, 2000, 
Wuchty et al., 1998, Zuker and Sankoff, 1984). In addition, smaller-sized aptamers 
allow for more desirable dimensions when constructing simple, compact, and highly 
sensitive and specific biosensors (Zhou, 2010). Moreover, the production of shorter-
sequence aptamers is easier and more cost effective (Shangguan and Tang Z., 2007). 
Accordingly, it is beneficial to determine and functionalise the minimal binding motifs 
of aptamers, particularly for diagnostic purposes. 
1.5.6.2 Approaches to aptamer optimisation by truncation 
The commonly used methods of determining the target-binding motifs of aptamers 
include enzymatic footprinting, partial hydrolysis, and in the case of RNA, in vitro 
transcription of the truncated sequence (Bing et al., 2010, Nonaka et al., 2010). With 
partial hydrolysis, multiple “mapping” attempts would have to be made and the 
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by chemical synthesis, before their binding capacity can be confirmed (Nonaka et al., 
2010). These approaches are often either too complex or time-consuming (Nonaka et al., 
2010).  For instance, radioactive labelling is needed during enzymatic footprinting in 
order to detect the aptamer fragments, and the cost for chemical synthesis of multiple 
versions of shorter sequences (generated from partial hydrolysis) for "trial and error" 
binding analyses would be expensive (Bing et al., 2010, Rockey et al., 2011). To 
circumvent some of these challenges, several groups have made use of computationally 
predicted secondary structures to deduce the target-binding motifs of aptamers and 
eliminate non-essential nucleotides (Nonaka et al., 2010, Rockey et al., 2011). This 
approach (Figure 1-4) termed “rational truncation (Rockey et al., 2011), eliminates the 
complexity and cost limitations of the “wet lab” experimental investigations mentioned 
above. The resultant shorter and potentially structurally fitter aptamers can then be 
appropriately modified and incorporated into sensing platforms, for the design of 
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1.5.7 Aptamers isolated against the ESAT-6.CFP-10 heterodimer as potential 
TB detection probes 
With the aim of exploiting the numerous advantages of aptamers and to generate 
detection probes for the design of a potential PoC TB diagnostic tools, recently 
published work from our research group at the CSIR, yielded ssDNA aptamers against 
the ESAT-6.CFP-10 heterodimer (Rotherham et al., 2012). The aptamers were isolated 
and screened for binding to the recombinant target proteins using the ELONA method 
previously described (Drolet et al., 1996). These aptamers showed affinity for the 
ESAT-6.CFP-10 heterodimer, as well as the CFP-10, and did not bind to the ESAT-6 
monomer (Rotherham et al., 2012). Furthermore, one of these aptamers called CSIR 
2.11 detected active TB in clinical sputum samples in ELONA readout format, with 
Figure 1-4: Schematic illustration of optimisation of aptamers by rational (secondary 
structure-guided) truncation. Rational truncation of the original full length sequences is 
carried out based on the predicted secondary structures, by removing non-essential parts 
of the sequence and retaining the predicted ligand-binding motifs. The truncated 
aptamer sequence is the folded into potential secondary structure to confirm the 
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100% sensitivity and 70% specificity, demonstrating potential clinical applications of 
these aptamers (Rotherham et al., 2012). 
Therefore, to help design a potentially effective aptamer-based PoC TB diagnostic kit, 
characterisation and post-SELEX optimisation of the anti-ESAT-6.CFP-10 aptamers 
was necessary. Characterisation would help determine the affinity and fitness of these 
aptamers as detection reagents. Furthermore, describing the secondary structural 
properties and associated energetics of the aptamers would give insight into what 
structural elements are primarily involved in their functionality, and how efficiently 
these aptamers fold into ligand-competent structures. Collectively, this information can 
guide the process of developing the anti-ESAT-6.CFP-10 aptamers as probes suitable 














1.6 Study aim and objectives 
The aim of this study was three-fold: (a) to characterise the interactions of the DNA 
aptamers previously isolated by our research group against the ESAT-6.CFP-10 
heterodimer (Rotherham et al., 2012); (b) to conduct the post-SELEX optimisation of 
these aptamers by rational truncation; and (c) to evaluate  the functional performance of 
the truncated aptamers in comparison to their parental molecules.  
The specific objectives were: 
o To characterise the binding of six anti-ESAT-6.CFP-10 aptamers by investigating 
their binding kinetics and structural properties. 
o To design truncated derivatives (based on predicted structural properties) of the 
aptamers, that would either bind similarly to, or better than the original parent 
sequences. 




















2.1 Ethics Statement 
No ethics approval was required for this study as neither human samples nor animal 
models were used.  
2.2 Bibliography Formatting and Referencing 
The Harvard referencing style was used in the current study.  
2.3 Protein Technology 
Prior to characterisation of aptamer-protein interactions, recombinant CFP-10 and 
ESAT-6 proteins were expressed and purified. Each protein was expressed separately as 
a monomer before in vitro dimerization was carried out to produce the ESAT-6.CFP-10 
heterodimer as previously described  (Renshaw et al., 2002). 
2.3.1 Expression and purification of CFP-10  
The protein expression and purification protocols used in this study were performed as 
previously described (Renshaw et al., 2002). Briefly, primary cultures were set up using 
glycerol stocks previously prepared by Lia Rotherham (Rotherham et al., 2012). The 
glycerol stocks consisted of E .coli BL21 (DE3) cells (Novagen, Merck) transformed 
with the T7 promoter-based expression plasmid, pMRLB46 (Megan Lucas, Colorado 
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2.3.1.1 Expression of recombinant CFP-10 
To prepare the starter cultures for CFP-10 expression, 25mL of Luria-Bertani (LB) broth 
culture medium (Sigma) supplemented with 100 µg/ml ampicillin (Sigma) were 
inoculated with a glycerol stock. The bacterial cultures were grown overnight at 37°C in 
a shaking incubator at 200 revolutions per minute (rpm). The overnight starter cultures 
were then inoculated into 2-L Erlenmeyer flasks, containing 1 L of fresh LB medium 
and 100 µg/ml ampicillin, and left to grow at 37°C in a shaking incubator at 200 rpm. 
CFP-10 expression was induced at mid-log (exponential) phase (OD 0.6, at 600 nm), by 
the addition of isopropyl-1-thio-β-D-galactopyranoside (IPTG; Sigma) at a final 
concentration of 0.4 mM. The CFP-10 cultures were harvested 4 hours after induction 
by centrifugation at 6500 rpm (~7800×g) for 20 minutes at 4°C. The cell pellets were 
stored at -80°C prior to purification. 
2.3.1.2 Purification of recombinant CFP-10 
The cell pellets were thawed and subsequently lysed by the addition of 10 ml of a 1:10 
Bacterial Protein Extraction Reagent (B-PER) (Thermo Scientific) diluted in ultrapure 
water. The B-PER is a lysis buffer consisting of a non-ionic detergent in 20mM Tris-
HCl, pH 7.5; lysozyme; and DNase I. The use of the B-PER reagent enabled mild 
extraction of proteins from bacterial cells without the need for mechanical disruption 
methods such as sonication. The B-PER reagent can be used for both soluble protein 
extraction and inclusion body purification from bacterial cell lysates. The lysed cell 
suspension was homogenised using a pipette, and incubated for 15 minutes at room 
temperature. Thereafter, the lysate was centrifuged at 15,000 × g for 15 minutes at 4°C 
to separate soluble from insoluble proteins. To capture the His-tagged CFP-10, the 
supernatant (cytosol fraction) was loaded onto a nickel-nitrilotriacetic acid (Ni-NTA) 
resin column (Bio-Rad), which had been pre-equilibrated with Buffer A (6 M urea 
[Sigma], 25 mM Tris-HCl [Sigma], 200 mM NaCl [Sigma], 10 mM imidazole, pH 7.4, 
[Merck]) by moderate rotation overnight at 4°C. The resin was washed six times with 10 
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respectively. The column was then subjected to two washes with 20 mL of Buffer B (25 
mM Tris-HCl [Sigma], 200 mM NaCl [Sigma], 10 mM imidazole [Merck], pH 7.4). The 
washes were collected at each step, and stored at 4°C for gel analysis. Finally, the His-
tagged CFP-10 was eluted in a single step with 10 ml of Buffer B containing 300 mM 
imidazole. The eluate was collected, divided into 1 ml aliquots and stored at -80°C. 
2.3.2 Expression and purification of ESAT-6 
Expression of ESAT-6 was performed according to a protocol similar to that used for 
CFP-10 (outlined above), with some modifications. Similarly, primary cultures were set 
up form glycerol stocks made by Lia Rotherham (Rotherham et al., 2012). The stocks 
consisted of E. coli BL21 (DE3) cells (Novagen) transformed with the T7 promoter-
based expression plasmids pMRLB7, expressing full-length N-terminal hexahistidine 
tagged ESAT-6 protein. 
2.3.2.1 Expression of recombinant ESAT-6 
The ESAT-6 overnight starter cultures were set up as described for CFP-10 above. 
Expression of ESAT-6 was induced at mid-log phase (OD = 0.6, at 600 nm), by the 
addition of IPTG (Sigma) at a final concentration of 0.4 mM. However, unlike the CFP-
10 cultures, the induced ESAT-6 cultures were incubated overnight at 25°C. The post-
induction incubation at 25°C was conducted to increase the solubility of ESAT-6. 
ESAT-6 enters inclusion bodies when induced at 37°C (Renshaw et al., 2002). Previous 
studies about expression of MTB antigens reported that reducing the culture growth 
temperature helps enhance the solubility of the expressed protein (Chaudhary et al., 
2005, Kulshrestha et al., 2005). Following the overnight incubation, harvesting of the 
cells was achieved by centrifugation at 6500 rpm for 20 minutes at 4°C. The ESAT-6 -
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2.3.2.2 Purification of recombinant ESAT-6  
ESAT-6 was purified from the supernatant using a protocol similar to that used for CFP-
10, except that the Ni-NTA column was washed with 20 mL of Buffer B containing 40 
mM and 50 mM imidazole, respectively, prior to elution of the ESAT-6 protein in 300 
mM imidazole as described above.  
2.3.3 Concentration of Proteins: CFP-10 and ESAT-6 
The CFP-10 and ESAT-6 proteins were concentrated through a buffer exchange process 
using the Vivaspin-6, 3 KD cut-off membrane columns), according to manufacturer’s 
instructions (Sartorius Stedim Biotech). The buffer exchange process consisted of 
repetitive steps of loading of the column with Hepes buffer (200 mM Hepes, 200 mM 
NaCl, pH 2.5), followed by centrifugation at 4°C and 4500 rpm, and subsequent 
decanting and loading of fresh buffer after every centrifugation step. Following six 
repeats of this process, the protein was finally displaced from the membrane by gently 
pipetting the 1mL buffer remaining in the sample loading part of the column over the 
column membrane. The concentrated protein was collected in 1mL fractions and stored 
at -80°C. 
2.3.4 Analysis of CFP-10 and ESAT-6 proteins by Sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS–PAGE) 
SDS-PAGE was used to resolve the proteins according to their molecular weight. SDS is 
an anionic detergent known to denature secondary and non–disulfide–linked tertiary 
structures, and confer a negative charge to each protein in proportion to its mass. A 
discontinuous buffer system with a stacking and resolving gel was used to increase the 
resolution of protein separation during electrophoresis. The gels were prepared using the 
Bio-Rad mini-Protean 3 system. A resolving gel was prepared first with the composition 
described in Table 2-1. The gel was poured into the gel cast, and subsequently layered 
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was removed and a stacking gel (Table 2-2), was layered over the resolving gel and 



















Once the gels had set, each protein sample was mixed a 1:1 ratio with a 2 × Laemmli 
samples buffer (63 mM Tris-HCl (pH 6.8, 10% Glycerol, 2% SDS, 2% (v/v) 2-
mercaptoethanol, 0.1% (w/v) Bromophenol Blue) prior to denaturation at 95°C for 5 
minutes. Following denaturation, the protein samples were resolved on the 
discontinuous buffer gels using the mini-Protean 3 system (Bio-Rad). The gels were 
Table 2-1: Composition of Resolving gel for SDS-PAGE 
Separating gel solution (17%) 10 mL  
1.5 M Tris–HCl [Sigma], pH 8.8 (0. 1% SDS) 
[Sigma] 
2.5 ml  
Acrylamide/Bis–acrylamide (40% w/v)     [Sigma]              4.25 ml 
ddH2O  3.14  ml 
10% (w/v) ammonium persulfate (APS) [Sigma] 100 μl  




Table 2-2: Composition of Stacking gel for SDS-PAGE   
Stacking gel solution (4%) 5 mL  
0.5 M Tris–HCl (Sigma), pH 6.8, (0.1%) SDS 
(Sigma) 
1 ml  
Acrylamide/Bis–acrylamide (40% w/v)                              0.5 ml 
ddH2O 3.45 ml  
10% (w/v) ammonium per sulfate (APS)  50 μl  
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electrophoresed in 1×Tris-Glycine buffer (25 mM Tris base, 192 mM Glycine, pH 8.3) 
at 30mA for 1 hour. The leading ions of the gel (as indicated by the blue dye) were 
allowed to diffuse through the gel before electrophoresis was stopped. The gels were 
then removed from the Bio-Rad mini Protean system, and  rinsed in distilled water 
before staining with Coomassie brilliant blue R-250 (0.25% Coomassie Blue R-250 
(Sigma), 50% Methanol (Merck) and 10% acetic acid (Merck). Following sufficient 
staining, the gels were destained using a solution of 50% Methanol (Merck), 40% acetic 
acid (Merck), and 10% ddH2O and viewed on the Molecular Imager Chemidoc XRS+ 
Imaging system (Bio-Rad). 
2.3.5 Western blot analysis of CFP-10 and ESAT-6 proteins 
Western blot analysis was used to confirm the presence of CFP-10 and ESAT-6 using 
their cognate antibodies. Purified CFP-10 and ESAT-6 were respectively resolved on a 
17% SDS-PAGE at 30 mA as described above. The proteins were then electro-blotted 
onto a Hybond™-enhanced chemi-luminescence (ECL) nitrocellulose membranes (GE 
Healthcare) using a Trans-Blot® Semi-Dry (SD) Transfer Cell (Bio-Rad). To limit non-
specific binding, the membranes were blocked by incubation in PBS supplemented with 
0.005 % (v/v) Tween-20 (Sigma, USA) and 5% (w/v) fat-free milk powder for 1 hour at 
room temperature. Blocking was followed by a 1 hour incubation at room temperature, 
with a 1:15,000 dilution of the respective primary (anti-CFP10 polyclonal antibody 
(provided by Megan Lucas, Colorado State University) or a monoclonal mouse anti-
ESAT-6 antibody (Santa Cruz Biotechnology). The membranes were washed three 
times with wash buffer (PBS containing 0.005% Tween-20), and incubated for 1 hour 
with 1:15,000 dilution of the horseradish peroxidase-(HRP) conjugated secondary 
antibodies: HRP goat anti-rabbit IgG and HRP goat anti-mouse IgG, respectively (Santa 
Cruz Biotechnology). Following three washes, the proteins were detected with ECL 
Advance™ Western Blotting Detection kit (GE Healthcare) according to the 
manufacturer’s instructions. Western blot imaging and analysis was conducted on the 
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2.3.6 Determination of protein concentration 
The Pierce® bicinchoninic acid (BCA) Protein Assay Kit was used to quantify ESAT-6 
and CFP-10, respectively. The BCA method is based on the combined reduction of 
Cu+2 to Cu+1 by protein in an alkaline medium (the biuret reaction), and the highly 
sensitive and selective colorimetric detection of Cu+1. The chelation of two molecules 
of BCA with one cuprous ion in the assay results in a purple-coloured reaction product. 
This water-soluble complex exhibits a strong and nearly linear absorbance at 562 nm 
over a broad working range (20-2,000 μg/mL). The BCA protocol in the current study 
was carried out according to the manufacturer’s manual. Briefly, a standard curve for 
the protein micro assay was set up according to OD595 nm against a concentration of 
Bovine Serum Albumin (BSA) standards. Following incubation at 37°C for 30 min, 
absorbance was measured against the reagent blank and the unknowns (ESAT-6 and 
CFP-10) were extrapolated from the standard curve. 
2.3.7 In vitro formation of the CFP-10 and ESAT-6 heterodimer complex  
The purified ESAT-6 and CFP-10 recombinant proteins were mixed in 1:1 molar 
amounts (5 µM) in a phosphate buffer (25 mM NaH2PO4, 100 mM NaCl, pH 7.5), as 
previously described by (Renshaw et al., 2002). The ESAT-6.CFP-10 dimer was then 
analysed by native or non-denaturing PAGE. The non-denaturing gels and running 
buffer were prepared in the same way as the SDS-PAGE, but without the SDS, which is 
the denaturant. 
2.4 DNA Technology 
The full length aptamers used in this study were generated from a previous study 
(Rotherham et al., 2012) through the SELEX process.  
2.4.1 Isolation of Plasmid DNA 
To produce template DNA plasmids for the intended production of dsDNA, glycerol 
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resultant aptamer pools had been ligated into plasmid vectors (pGEM-T Easy vector) 
(Promega) to produce individual aptamer clones (Rotherham et al., 2012). Starter 
cultures for each aptamer were prepared by inoculating a single colony from an aptamer 
glycerol stock into 10ml of LB medium (Sigma) supplemented with 100 µg/ml 
ampicillin (Sigma). The starter cultures were grown overnight (~12 hours) in a shaking 
incubator, at 37°C with vigorous shaking (300 rpm. Each starter culture was inoculated 
into 200mL of LB medium, and grown at 37°C with vigorous shaking (300 rpm). The 
cultures were grown in flasks with a volume capacity of at least four times the volume 
of each culture to allow for proper aeration. The bacterial cells were harvested by 
centrifugation at 6000 × g for 15 minutes at 4°C.  
Cell lysis and plasmid preparations were carried out using the Plasmid Maxi Kit 
(QIAGEN) according to the manufacturer’s protocol. The concentration of the plasmid 
DNA was quantified using the NanoDrop® 1000 spectrophotometer. The purity of the 
plasmid DNA was assessed by 1% agarose gel electrophoresis with Ethidium Bromide 
staining. 
2.4.2 PCR amplification of Plasmid DNA 
Polymerase chain reaction (PCR) was used to produce and amplify the dsDNA required 
to make functional ssDNA for further characterisation of the aptamers. The template 
DNA used in this experiment was from the plasmids described above. The following 
primers; forward primer: 5′-biotin-GCCTGTTGTGAGCCTCCTAAC-3′, reverse 
primer: 5′-phosphate-GGGAGACAAGAATAAGCATG-3′, were purchased from 
Integrated DNA Technologies (IDT). Usually, about 100ng of template DNA was used 
per PCR reaction. All PCR reactions were set up in 100 μl of reaction volume (Table 2-
3) The PCR protocol was as follows: initial denaturing step at 95°C for 2 minutes; 
twenty cycles of denaturing step at 95°C for 30 seconds, an elongation step at 56°C for 
30 seconds and an extension step at 72°C for 30 seconds; final extension was performed 

























2.4.3 Purification of PCR product  
To purify the PCR product and remove free nucleotides from the DNA samples, a 
Promega PCR clean-up kit was used according to the manufacture’s protocol. The 
concentration of the dsDNA was calculated from absorbance readings at 260 nM. The 
purified dsDNA was analysed by non-denaturing PAGE. 
2.4.4 Lambda exonuclease digestion for generation of ssDNA   
To generate ssDNA from the dsDNA, the PCR product was digested using lambda (λ) 
exonuclease, as previously described (Avci-Adali et al., 2009). The λ exonuclease is a 5′ 
to 3′ exodeoxyribonuclease; an enzyme that selectively digests the phospohorylated 
strand of dsDNA (Figure 2-1). The enzyme is known to exhibit greatly reduced activity 
on ssDNA and non–phospohorylated dsDNA (Higuchi and Ochman, 1989). In the 
current study, 10 U of λ exonuclease (New England Biolabs) were used to digest 6.6μg 
of purified dsDNA in a total volume of 100 μl with 1× λ exonuclease buffer. The 
exonuclease mixture was incubated at 37°C for 4 hours, after which the reaction was 
Table 2-3: Composition of one PCR reaction mix (of 100 ml)  
Stock   Final concentration  Volume  
Template DNA  10–100 ng  0.5–1 μl 
5×Taq Buffer  1×  20 μl 
MgCl2   1.5mM 14 μl 
10 mM GeneAmp® 
dNTPs (Invitrogen) 
0.2 mM  2 μl  
100 µM forward primer  1 μM  1 μl 
100 µM reverse primer  1 μM  1 μl 
Taq Polymerase (5U/μl)  25 U/ml  0.5 μl  
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terminated by incubation at 70°C for 10 min. The resultant ssDNA (biotinylated strand) 
was purified using the Nucleospin® Extract II kit (Machery-Nagel), and analysed by 
non-denaturing polyacrylamide gel electrophoresis. 
5’- GCCTGTTGTGAGCCTCCTAAC    (N40)  CATGCTTATTCTTGTCTCCC  - 3’  
3’-GTACGAATAAGAACAGAGGG- - 5’P
5’- -GCCTGTTGTGAGCCTCCTAAC-3’ B




Lambda Exonuclease Digestion 
ssDNA
GTACGAATAAGAACAGAGGG- - 5’P3’- CGGACAACACTCGGAGGATTG (N40) 
B
GTACGAATAAGAACAGAGGG-5’ 3’-CGGACAACACTCGGAGGATTG  (N40) 
5’- - GCCTGTTGTGAGCCTCCTAAC  (N40)  CATGCTTATTCTTGTCTCCC 3’B
PCR
P =  Phosphate 
B =  Biotin 
 
2.4.5 Analysis of DNA by gel electrophoresis 
The DNA aptamers were analysed by electrophoresis. Agarose gels were used to resolve 
the plasmid DNA, while polyacrylamide gels were used for the PCR product and the 
ssDNA. 
Figure 2-1: Schematic illustration of ssDNA production of selected anti-ESAT-6.CFP-
10 aptamers. The dsDNA was produced by PCR using the relevant primers. The reverse 
primer, which was 5′ phosphate-modified enables Lambda exonuclease digestion, which 
selectively digests the phosphorylated strand of the dsDNA. The remaining strand 
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2.4.5.1 Agarose gel electrophoresis  
Agarose gel electrophoresis is commonly used to resolve larger fragments of DNA. 
Usually, 2% agarose gels are used for dsDNA with less than 100 bp, and 1% gels for 
larger DNA fragments. The plasmids of the aptamer clones in the current study were 
resolved on 1% agarose gels. To prepare the gel, agarose powder (Sigma) was mixed 
with 1× TBE (89 mM Tris-borate, 2 mM EDTA, pH 8.3) to the desired concentration. 
For 1% gels, 1g of agarose powder was dissolved in 100 mL of 1× TBE, and heated in a 
microwave until completely melted. The gel mixture was left to cool to about 60°C, 
after which Ethidium Bromide was added to the agarose mix to a final concentration of 
0.5μg/ml.  
To prepare the DNA samples for loading on the gel, 6× DNA loading buffer 
(Fermentas) was added to each sample, and 50 ng of DNA were loaded in each well. 
The MassRuler DNA ladder mix (Thermo Scientific) was loaded in a separate well and 
used as a reference with which to confirm the molecular weight of the DNA samples. 
The gel was electrophoresed in 1× TBE (89 mM Tris-borate, 2 mM EDTA, pH 8.3) 
buffer at 100V. The gels were visualized under ultraviolet (UV) light using the 
Molecular Imager Chemidoc XRS+ Imaging system (Bio-Rad). 
2.4.5.2 Non-denaturing (Native) polyacrylamide gel electrophoresis 
Polyacrylamide gels are generally used to separate shorter nucleic acids. In the case of 
non-denaturing or native polyacrylamide gels, nucleic acids migrate at different rates, 
based on their secondary structure. In contrast, nucleic acids run as single-stranded 
fragments on denaturing gels. Under denaturing conditions, the secondary structure of 
the nucleic acid does not form, and thus only the length of the molecule will affect 
mobility. 
The nondenaturing polyacrylamide gel mixtures used in this study were prepared using 
the compositions outlined in Table 2-4. The DNA samples were prepared for 
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About 50 ng of DNA were loaded in each well, and a GeneRuler Low Range DNA 
Ladder (Fermentas) was loaded in a separate well to confirm the molecular weight of the 
DNA samples. The gels were electrophoresed in 1× TBE buffer at 100V followed by 
Ethidium Bromide staining and visualization using Molecular Imager Chemidoc XRS+ 










2.5 Characterisation of molecular interactions of full length aptamers with 
target proteins 
Six of the aptamers that showed the best binding profiles during the initial screening for 
binding to recombinant target using ELONA (Rotherham et al., 2012) were selected for 
further characterisation. Given that the yield of ssDNA from lambda exonuclease 
digestions was insufficient for downstream assays, chemically synthesised aptamers 
were obtained from IDT. The aptamers were synthesised with a 5′-Biotin modification 
to enable for detection using Streptavidin-conjugated HRP-catalysed reactions in 
ELONAs.  
Table 2-4: Polyacrylamide gel composition for DNA analysis 
10% Non-denaturing Polyacrylamide gel (12%) 10 ml 
Acrylamide/Bis–acrylamide (40% w/v)     
[Sigma]              
3 ml 
10 × TBE buffer  (1 × final concentration)  1 ml  
10% (w/v) ammonium per sulfate (APS)  100 μl 
TEMED  10 μl  
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2.5.1 Surface Plasmon Resonance (SPR) technology-based determination of 
aptamer dissociation constant (KD) values 
To determine binding affinities of the aptamers to the target, SPR technology was used. 
Briefly, target protein (CFP-10) was immobilised unto a CMD 500 biosensor chips 
(Xantec) on a BIAcore® 3000 biosensor instrument (GE Healthcare).  This was followed 
by the injection of serial dilutions of the analyte (respective aptamers) over the ligand 
surface at a constant flow rate. The ligand-target interactions were then measured by the 
SPR instrument as changes in the refractive index, recorded as response units (RU).  
2.5.1.1 Preparation of chip surface and immobilisation of ligand 
To activate the carboxy-methylated dextran surface of the biosensor chips, 50 μl of a 1:1 
combination of 0.5 M N-hydroxysuccinimide (NHS), 0.2 M N-ethyl-N'-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) (Biacore, GE Healthcare) was 
injected at a flow rate of 10 μl/minute, over all the four flow cells of the biosensor chip. 
The activation step allows for amine coupling of the protein to the surface of the chip. 
Activation was followed by injection of 50 μl of the in-house-purified CFP-10 monomer 
diluted to 0.015 mg/ml/ (1.5 μM) in 100 μl acetate buffer (10 mM, pH 4.5), into three of 
the four flow cells (1 to 3). Approximately 3000 RU of CFP-10 were coupled. Flow cell 
4 was used as the control (reference flow cell with no protein). Ethanolamine-HCl (1 M, 
pH 8.0) was injected over the immobilised protein to block the remaining activated 
carboxymethyl groups. This was followed by the injection of 35 μl of 10 mM NaOH 
(regeneration solution) to reduce any non-specific binding that remain after the 
ethanolamine-HCl blocking step. 
2.5.1.2 Preparation of aptamers 
Aptamer stocks were prepared by reconstituting the lyophilised chemically synthesised 
ssDNA aptamers (IDT) in water to a final concentration of 100 μM. The ssDNA 
aptamers were run on a native polyacrylamide gel for independent validation and 
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in refolding (selection) buffer (1× final concentration); HMCKN buffer consisting of 10 
mM Hepes pH 7.4, 1 mM MgCl2, 1 mM CaCl2, 2.7 mM KCl, 150 mM NaCl). The 
aptamers were diluted to give a series of concentrations: 31 nM, 62 nM, 125 nM, 250 
nM, and 500 nM.  
2.5.1.3 Injection of aptamers over the CFP-10-coated sensor chip surface 
Prior to injecting the aptamers, 50 µl of 1× HMCKN buffer was injected across all four 
flow cells; to control for the buffering effect. The aptamers were heated to 95°C for 
5min, and rapidly cooled at 4°C, briefly settled at room temperature before they were 
injected over the surface at a flow rate of 10 μl/min (to minimize mass transfer 
limitations). ssDNA aptamers at concentrations 500, 250, 125, 62, 31 nM, were then 
injected over all four flow cells. The binding events (aptamer-protein interactions) were 
recorded by the SPR instrument. The aptamers were allowed a 600 seconds dissociation 
time before the sensor chip was regenerated using 10μl of 10mM NaOH after each 
aptamer binding step. This was done for each of the six selected ssDNA aptamers. Bulk 
shift and non-specific interactions with the CFP-10 were subtracted using the response 
from a reference flow cell (flow cell 4), which did not contain CFP-10. Figure 2-2 
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Analysis of data obtained in these experiments was performed using the BiaEvaluation 
Software (BIAcore). The software allowed for calculations of the association and 
dissociation constants, from which equilibrium dissociation constant (KD) values were 
determined. Resulting data were prepared for kinetic analysis by resetting the time and 
RU to zero, respectively, before the first injection. To control for refractive index 
changes and nonspecific binding, the responses from the control flow cell (no protein) 
were subtracted from those generated for the aptamer-CFP-10 interaction. The affinity 
of the aptamers, as described by the KD, was determined by globally fitting the binding 
data to the kinetic simultaneous ka/kd model, assuming Langmuir (1:1) binding. The 
Figure 2-2: Schematic representation of the process of evaluation of ssDNA aptamer-














 49   
 
model follows pseudo-first order kinetics and assumes that binding is equivalent and 
independent for all binding sites. The Chi2 values for the dissociation constants were 
determined, as a measure of the reliability of data.  
2.5.2 Characterisation of the ssDNA aptamers-ESAT-6/CFP-10 heterodimer 
interactions using EMSA 
The kinetic interactions between the ssDNA aptamers and the ESAT-6.CFP-10 
heterodimer were investigated by EMSA. SPR could not be used because the ESAT-
6.CFP-10 dimer complex is held together by salt bridges and this poses a challenge in 
the stability of the protein during SPR experiments. Due to the relatively harsh pH 
conditions of the SPR ligand buffer, and the constant flow of buffers in the microfluidic 
environment of the sensor chip on which the protein is immobilised, as well as the 
regeneration of the sensor chip using NaOH after every aptamer binding event, the 
dynamics in the SPR instrument may not be favourable for the stability of the 
heterodimer. As an attempt to circumvent the above-mentioned technical hurdles, 
EMSA was considered a good alternative technique to assess the molecular interactions 
and stoichiometric interactions between the aptamers and the ESAT-6.CFP-10 dimer. 
In a typical EMSA experiment, a nucleic acid is labelled at the 5′-end label with 
radioisotope 32P, and subsequently incubated with increasing amounts of target protein, 
followed by electrophoresis of the aptamer-protein complexes, and analysis of mobility 
using a phosphoimager or autoradiograph (Figure 2-3). From this, the amount of bound 
and unbound aptamer can be quantified. 
The EMSA protocol used in the current study was adapted from (Buratowski and 
Chodosh, 2001). The process is divided into several parts, namely, radioactive labelling 





















2.5.2.1 Labelling of the ssDNA aptamer probe 
The in-house produced CSIR 2.11 aptamer was used for the EMSA experiments. For the 
5′ end labelling reaction, 50 pmol of CSIR 2.11 was mixed with 50 pmol (150 μCi) γ-32P 
ATP (PerkinElmer) (specific activity 3,000 Ci/mmol), 10 × Polynucleotide Kinase 
(PNK) Buffer, 20 U of the enzyme PNK (Perkin Elmer), in a 1.5 ml Eppendorf tube, and 
nuclease-free water was added to a final volume of 20 μl. The mixture was incubated for 
60 min at 37oC, after which the reaction was stopped by adding 1 μl of 0.5 M EDTA. 
The labelled DNA was separated from free ATP using Ambion nuclease-free NucAway 
Spin Columns (Invitrogen), according to the manufacturer’s instructions. To determine 
if the labelling was effective, the labelled DNA was electrophoresed on a 8% non-
denaturing polyacrylamide gel, which had been pre-run in 1 × running buffer, for 60 
Figure 2-3: Schematic flow diagram describing the EMSA process. A ssDNA probe is 
radiolabelled (A), after which the probe is incubated with its cognate protein and 
subjected to gel electrophoresis (B). Finally, the electrophoresed samples are imaged 
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min at 100 V. Electrophoresis of the labelled CSIR 2.11 was carried out at 30 mA for 30 
to 45 min.   
2.5.2.2 Preparation of binding reactions  
The binding reactions were prepared in 1.5 ml Eppendorf tubes. Radio-labelled CSIR 
2.11 was mixed with 1 × HMCKN buffer to a final concentration of 3 ng/µl. To allow 
for refolding, the aptamer was heat-denatured at 95oC for 5 minutes, and quickly cooled 
on ice for 5 minutes, and finally incubated at room temperature for 5 minutes prior to 
addition of protein. Increasing concentrations of protein were then added to the mix. The 
first aptamer-dimer reaction attempts were carried out with a lower concentration range: 
25, 50, 100, 150, 200, 250, 300, and 350 nM. Subsequent attempts were conducted 
using higher concentration ranges 250 nM, 350 nM, and 1 μM, and later 1, 5 and 10 μM. 
Glycerol was added to a final concentration of 10 % v/v, to facilitate sample loading and 
to enable the samples to sink and settle to the bottom of the wells of the gel. The final 
reaction volume was adjusted to 20 μl. The reaction mixtures were mixed gently by 
tapping the bottom of the tube with a finger, and incubated for 1 hour at room 
temperature. 
2.5.2.3 PAGE analysis of aptamer-protein complexes 
Following the 1 hour incubation, binding reactions were loaded (without loading buffer 
or dyes) into the appropriate wells of the native PAGE gel that had been pre-run for 30 
minutes. A small volume of 6× DNA loading dye (Fermentas) was loaded into a 
separate well, and was used to monitor the progress of the electrophoresis. 
2.5.2.3.1 Electrophoresis of aptamer-protein complexes 
The binding reactions were electrophoresed at 30mA for 45 minutes at room 
temperature. The recommended minimum time required to give good separation of free 
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Fried, 2007). Electrophoresis was then stopped before the bromophenol blue of the 
loading dye approached the bottom of the gel. 
2.5.2.3.2 Processing and analysis of the gel 
The glass plates were removed from the gel box, and carefully separated. The gel 
remained attached to one of the plates. The plate with the gel was laid on the bench with 
the gel facing up, and subsequently sandwiched with a sheet of Whatman 3 μm filter 
paper cut to size. The filter paper was then peeled off from the plate with the gel 
attached to it, and covered with a single layer of plastic wrap (without introducing any 
bubbles) and placed on a gel drier. The gel was then dried under vacuum for 75min: the 
first 15 minutes only the vacuum was applied, and the 60oC heat was only introduced 
after the 15 minutes. Following thorough drying, the gel was placed in a cassette (Bio-
Rad) and exposed, overnight, to a phosphor-imaging screen (Bio-Rad). The gel image 
was obtained using a phosphoimager; the Personal FX Molecular imager (Bio-Rad), at a 
high scan resolution of 50 microns. 
2.6 Structural characterisation of full length aptamers  
The mfold program (http://mfold.bioinfo.rpi.edu/cgi-bin/dna-form1.cgi) was used at 
default settings, and allowed for estimations of the MFE secondary structures of 
aptamers. The temperature was set to 37°C; salt conditions were at 1.0M NaCl. The 
difference in free energy between the MFE and the suboptimal structures within the 
same energy range (percent suboptimality), was set to 5. The factor that determines how 
different the secondary structures should be relative to one another (upper bound) was 
set to 50, while the maximum distance between base pairs was set to “no limit”. 
2.7 Optimisation of full length aptamers by rational (secondary structure-
guided) truncation 
Two aptamers, namely CSIR 2.11 and CSIR 2.19, were selected for optimisation 
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dissociation constants (Table 3-1). In addition, CSIR 2.11 had already been tested for its 
ability to accurately detect the target proteins in clinical samples (Rotherham et al., 
2012). The two aptamers were truncated through a series of 5′ and 3′-end base deletions 
to the shortest possible sequences that retained the mfold predicted secondary structures, 
and potentially the functional motifs of the original full length sequences.  
2.8 Computational analysis of folding behaviour of the full length aptamers 
versus the truncated aptamers: energetics and folding kinetics 
The Vienna RNA Package algorithms were used to probe the folding dynamics and 
kinetics of the truncated and parental full length aptamers as previously described 
(Flamm et al., 2002 
, Gruber et al., 2008, Lorenz et al., 2011). Specifically, the Barriers program 
(http://rna.tbi.univie.ac.at/cgi-bin/barriers.cgi) was utilised for conformational energy 
landscape analysis of the two ssDNA aptamers, CSIR 2.11 and 2.19 and their respective 
truncated derivatives. 
2.8.1 Conformational energy landscape analysis of aptamers 
Barrier trees were constructed using the default settings of the program, as follows: 1) 
basic options accounting for maximal number 50 of local minima, considering only 
minima with barrier height higher than 0.1 (and avoiding isolated pairs), and 2) 
advanced options were set for DNA energy parameters at 37°C. The program generated 
barrier trees representing only the 50 lowest local minima as a representative ensemble 
of conformations. The Barriers program uses a “flooding algorithm” that starts from an 
energy sorted list of all low energy conformations. This list may contain either all 
possible conformations or only those below a given energy threshold. From this, 
thermodynamic neighbours of the MFE structure are identified in the form of local 
minima and saddle points, which are presented on an energy barrier tree. Ultimately, the 
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theoretically describe the kinetics on the landscape without the need for complex 
computational simulations. 
2.8.2 Folding dynamics analysis: computational prediction of folding 
transition rates  
The program treekin (part of Barriers) was used to compute the folding dynamics of the 
investigated aptamers. The program uses macrostates and transition rates computed by 
the barriers program to give a visual image of the folding process and the occupancy of 
meta-stable states over time (Gruber et al., 2008, Lorenz et al., 2011). To simulate the 
folding kinetics in the current study, the first step was to compute an energy landscape 
(represented in the form of a barrier tree) using the barriers program. This was followed 
by choosing an initial structure (representing the open chain), as well as a start and end 
time (these were user-determined) for the folding kinetics simulations using the treekin 
part of the barriers program. The treekin program then computed population densities as 
a function of time (with arbitrary units). For example, if the selected start structure (p0) 
is set to be macrostate 2 (the second lowest local minimum in the barrier tree), and the 
sum of the all population densities equals 1, the simulation will start with 100% of the 
initial population in macrostate 2. The transition rate matrix is constructed beginning at 
the start structure along the path to the MFE structure (macrostate 1 on the barrier tree). 
The output from these computations is a graph that shows percentage population 
densities (y-axis) over time in arbitrary units (x-axis). This information gives a 
theoretical model of the folding or refolding time from an open-chain structure to a 
stable target-compatible MFE structure of an aptamer.  
2.9 Analysis of binding of truncated aptamers by ELONA 
The rationally truncated aptamers were tested for binding to target proteins in an 
ELONA, under the same conditions as those used to test the binding of the full length 
aptamer as previously described (Rotherham et al. 2012). Briefly, 96-well high binding 
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CFP-10 monomer (prepared in 100 µl of 1 × NaHCO3 coating buffer) and incubated at 4 
°C overnight. The control wells were only coated with the 1 × NaHCO3 coating buffer. 
Following the incubation period, the plate was decanted and wells were then washed 
three times with 150 µl of Phosphate Buffered Saline containing 0.05% Tween (PBS-T) 
buffer (Sigma), and blocked with 5% fat-free milk in PBS-T for 1 hour. This was 
followed by a further three wash steps with PBS-T. The biotinylated aptamers were 
prepared in 1× HMCKN (refolding buffer) to a final concentration of 500 nM, heated to 
95°C and then cooled quickly to 4°C, before 50 µl aliquots of each aptamer were added 
to the appropriate wells and incubated for 2 hours at room temperature. Following 
aptamer incubation, the plate was washed four times with PBS-T, after which 100 µl of 
1:15,000 Streptavidin-HRP conjugate (Kirkegaard & Perry Laboratories, KPL) was 
added to the wells, and incubated for 2 hours at 37 °C. Following the washing steps, 50 
µl of Turbo- 3, 3', 5,5'-tetramethylbenzidine (TMB) substrates mixed 1:1 
(Thermoscientific, Pierce) was added to each well, incubated for 15 min at 37 °C to 
enable detection of the biotin-labelled aptamers. The streptavidin-HRP: TMB reaction 
was stopped by the addition of 50 µl of H2SO4. The protein-bound aptamer-streptavidin 
complexes were quantified by absorbance measurements at 450 nm using the Multiskan-
Go plate reader (Thermo Scientific). All the test and control samples were evaluated in 
triplicate, in two independent experiments. 
2.9.1 Statistical analysis of ELONA-based evaluation of truncated aptamer 
binding to recombinant target proteins 
Further analysis of the data was based on the blank-subtracted values of each data point. 
The triplicate values were averaged and their standard deviation calculated. A two-tailed 
Student’s t-test was performed to determine statistical significance. To compare the 
performance of the truncated aptamers against their parent sequences, the relative 
binding of the respective aptamers was normalised to that of the 90-mer aptamer + CFP-


















3.1 Production of recombinant target proteins 
3.1.1 Expression and purification of ESAT -6 and CFP-10 
His-tagged recombinant CFP-10 and ESAT-6 proteins were successfully expressed, 
and confirmed through SDS-PAGE analysis of cell lysates from various stages of the 
protein expression process (Figure 3-1). The proteins were subsequently purified by 
nickel affinity chromatography, and analysed SDS-PAGE to confirm their integrity, 
size and purity (Figure 3-2). Purification was achieved, for the most part; however, 
one of the CFP-10 protein samples showed some contaminants on the gel. The 
identity of the proteins was determined by immunoblot analysis. The blot images 
showed reaction of the proteins with the respective antibodies (Figure 3-2). On 
average, 0.3 mg of CFP-10 was obtained per litre of culture. CFP-10 was found in 
the soluble fraction while ESAT-6 was found to be primarily expressed as an 
insoluble protein. The solubilisation of ESAT-6 was achieved through incubating the 
post-induction culture overnight at 25°C and the addition of urea as a chaotropic 
agent. The ESAT-6 yield was typically 0.1mg from 1 litre of culture. These yields 
were undesirably low and would be insufficient for use in functional assays with all 
the required optimisation steps. These yields were consistent through multiple 
expression and purification experiments. Therefore, to obtain sufficient protein, a 
number of repeat expressions and purification attempts would be required; all of 
which would be costly in terms of consumables and time. Consequently, large-scale 
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Figure 3-1: SDS-PAGE gel analysis of cell lysates from various 
stages of the protein expression process. Bacterial cultures of ESAT-6 
and CFP-10 were induced with IPTG and the cells were analysed for 
protein expression.  Lanes 2-9 represent the cultures sampled at 
different stages of expression (outlined above each well) prior to 
purification of protein. The circled bands represent the expressed 


















Figure 3-2: SDS-PAGE and Western Blot analysis of purified recombinant ESAT-6 
and CFP-10. Bacterial cultures expressing ESAT-6 and CFP-10 were purified by 
IMAC, and the proteins were resolved on 17% SDS-PAGE gel. (A) SDS-PAGE of 
purified CFP-10. (B) Western blot analysis of CFP-10. Purified ESAT-6 is shown on  
SDS-PAGE (C) and the western blot (D).The bands of the purified recombinant 
proteins (circled) on the SDS gels, are at appropriate sizes, as indicated by the  
















3.1.2 In vitro production of the ESAT-6.CFP-10 heterodimer complex  
To produce the ESAT-6.CFP-10 heterodimer complex in vitro, the recombinant 
CFP-10 and ESAT-6 monomers were mixed in equimolar amounts and dimerised in 
a phosphate buffer. The presence of the heterodimer complex was confirmed by non-
denaturing PAGE. Two bands were observed in the heterodimer complex lane. The 
lower and more intense band observed between the ESAT-6 and CFP-10 monomers 
depicts the heterodimer complex (Figure 3-3). The higher band in the heterodimer 
lane may represent the CFP-10 monomer that either did not form part of the dimer 
complex in the first instance or had dissociated during electrophoresis. Furthermore, 
the ESAT-6 monomer migrated farther than both the CFP-10 monomer and the 
ESAT-6.CFP-10 heterodimer complex.  
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Figure 3-3: Non-denaturing PAGE analysis of the ESAT-6 .CFP-10 
heterodimer. The heterodimer and respective composite monomers 
showed varying degrees of mobility as a result of structural 
















3.2 Production of ssDNA of selected aptamers 
As a starting point, plasmid DNA preparations were performed in order to produce 
template DNA for in-house production of the aptamers. The aptamer clones, which 
had been expressed in E.coli and stored as glycerol stocks were cultured, and their 
DNA subsequently extracted and purified. The presence and purity of the plasmid 




3.2.1 PCR amplification of ssDNA aptamers 
Following successful PCR amplification of selected aptamers, the quality, size and 
purity of the dsDNA were determined by non-denaturing PAGE (Figure 3-5). 
Generally, the wells showed distinct bands with no smears or laddering. The bands 
Figure 3-4: Agarose gel electrophoretic analysis of ssDNA plasmids. The isolated 
plasmids were purified and analysed by 1% agarose gel electrophoresis. 50 ng of 
DNA were loaded per well. The bands in lanes 2-7 represent purified plasmid DNA 
















in each well represent a single aptamer. The aptamers were at the expected sizes. 
Aptamer CSIR 2.15 has two bands which appear about 25bp apart.  
 
 
3.2.2 Purification of ssDNA aptamers 
To generate ssDNA, the dsDNA resulting from the PCR were digested using λ 
exonuclease. The enzyme selectively digested the 5'-phosphorylated strand of the 
dsDNA, leaving the complementary strand for use in functional assays. The efficacy 
of λ exonuclease-based ssDNA generation was verified by nondenaturing PAGE 
(Figure 3-6). The analysed samples showed no trace of dsDNA, indicating complete 
digestion of the phospohorylated strand. There are two bands in the CSIR 2.15 lane, 
as was the observed with the dsDNA form of the aptamer. The double bands suggest 
Figure 3-5: Native PAGE analysis of dsDNA after PCR amplification. The purified 
dsDNA was electrophoresed on a Native Polyacrylamide gel (8% Acrylamide). The 
bands represent the dsDNA of CSIR2.11 to CSIR 2.21. The bands of interest are at 
the expected size of 90bp. However, the PCR products of CSIR 2.2 and CSIR 2.15 
exhibited double bands. CSIR 2.2 has a lower fainter band, while CSIR2.15 lane has 
















the presence of two PCR products from the same plasmid; potentially resulting from 
one of the primers annealing to two different sequences in the plasmid. 
 
 
Although the production of ssDNA through PCR and exonuclease digestion was 
successful, the yields were inadequate for use in the functional assays. The 
maximum yields obtained in the current study were only about 40% of the maximum 
possible ssDNA amount that can be produced through λ exonuclease-based 
digestions. A similar trend was observed from several attempts of the exonuclease-
based generation of ssDNA. Therefore, to circumvent the cost and time demands of 
producing large amounts of dsDNA via in-house PCR, and performing a number of 
exonuclease digestions to generate adequate ssDNA, chemically synthesised ssDNA 
aptamers were purchased from IDT.  Only five of the six aptamers were synthesised; 
Figure 3-6: Native PAGE analysis of ssDNA after Lambda exonuclease digestion. 
To produce ssDNA, the dsDNA of each aptamer were treated with λ exonuclease, 
and subsequently purified. The purified ssDNA was then analysed by non-denaturing 
PAGE. The ssDNA bands run in the region of the expected sizes; between 50 and 
75bp. However, given that the ladder that was used was double-stranded, this does 
not allow for determination of exact size of the single stranded DNA aptamers. 

















CSIR 2.9 was excluded as it showed arbitrary binding kinetics (data shown in the 
next section). The sequences were sent to IDT, and the respective aptamers were 
synthesised in lyophilised form. Upon receipt, the lyophilised aptamers were 
reconstituted and their purity and molecular weight confirmed by non-denaturing 




3.3 Determination of binding kinetics of full length aptamers by SPR 
Aptamer-CFP-10 interactions were evaluated in real time using the Biacore 3000 
SPR instrument. The first step was to stably immobilise the CFP-10 protein on the 
Figure 3-7: Analysis of solid-phased synthesised aptamers by non-denaturing 
PAGE. The bands in the labelled lanes represent each the ssDNA aptamers at the 
expected molecular weight. However, it is important to note that ladder was double-
stranded, and therefore does not allow for determination of exact size of the single 
















sensor chip, to allow for subsequent aptamer binding (Figure 3-8). CSIR 2.2, 2.15, 
2.11 and 2.21 bound the CFP-10 target in a concentration-dependent manner (Figure 
3-9).  In contrast, CSIR 2.9 did not exhibit the expected concentration-dependent 



























Figure 3-8: Representative Sensorgram for the coupling of CFP-10 on an SPR 
sensor chip surface. Activation of the sensor chip was achieved by injecting the 
EDC:NHS over the surface of the chip to activate the Dextran matrix for amine 
coupling of the ligand. The ligand, in this case, CFP-10, was amine-coupled to the 
chip in flow cells (FC) 1 to 3. FC4 represents the blank, “no protein” control, which 
was used as a reference FC from which to subtract non-specific binding. 
Ethanolamine was used to block remaining active sites in the FC. To wash non-



















Figure 3-9: Binding Kinetics of full length aptamers evaluated by SPR. Sensorgrams 
show the interaction of immobilized CFP-10 on CMD500 chip (Xantec) with 
increasing concentrations of aptamers (31, 62, 125, 250, 250, and 500 nM). The flow 
rate was 10µl/min, each aptamer dilution was allowed a 600s dissociation time 
before regeneration of the sensor chip using 10mM NaCl. The BIAevaluation 
software was used to analyse the data. The blank flow cell and the buffering effect 
were corrected for in the analysis.  The KD values, which were calculated assuming 

















The kinetic parameters and associated statistics of the triplicate measurements of 
aptamer-CFP-10 interactions were calculated using the BIAevaluation software. The 
KD values depicting the ratio of the ‘on’ and ‘off’ rates of each aptamer were 
globally fitted for the five different concentrations using the Langmuir model 
assuming 1:1 ligand: analyte interaction. Five of the six full length aptamers had KD 
values within the low nanomolar range (Table 3-1), indicating tight binding of the 
aptamer to CFP-10. A good fit to the Langmuir model was obtained for these five 
aptamers, as demonstrated by the Chi2 values (Table 3-1). Each Chi2 value shown in 
the table is the highest of the three values for each data set (from the three flow cells, 
Appendix A 1.1.). The Chi2 is a statistical measure of closeness of fit of 
experimental data to the theoretical model used to determine the KD, i.e. it describes 
how well results agree with curve-fitting of the model used. Chi2 values lower than 
the noise RU (in this case, ~ 20 RU), indicate a good fit. Conversely, the data 
obtained from the kinetic analysis of CSIR 2.9 did not fit the 1:1 Langmuir model. 
Figure 3-10: Sensorgram showing binding Kinetics of full length CSIR 2.9 aptamer 
evaluated by SPR. The RU at 250nM was lower than the RU at 125nM, and the 

















Thus a KD value for this aptamer could not be derived under the same conditions as 
those of the other five aptamers.  
Aptamer Average KD Chi2 values 
CSIR 2.2 21.5nM ± 4.3nM 0.1 
CSIR 2.11* 9.0nM ± 1.7nM 0.1 
CSIR 2.15 12.8nM ± 1.6nM 1.4 
CSIR2.19 1.6nM ± 0.5nM 0.3 




3.4 Determination of CSIR 2.11-ESAT.CFP-10 dimer interactions by EMSA 
EMSA experiments were performed with the aim of assessing the interactions 
between the aptamers and the ESAT-6.CFP-10 heterodimer, and the CFP-10 
monomer, and to potentially characterise the kinetic parameters thereof. For these 
experiments, the in-house-produced CSIR 2.11 aptamer was used. The aptamer was 
radioactively labelled at the 5' end with γ-32P, and the labelling was verified by non-
denaturing PAGE (Figure 3-11).  
The EMSA results did not demonstrate strong binding of the aptamer to the proteins. 
For the most part, the electrophoresed samples did not show a discernible shift, and 
in some cases did not form single discrete bands. In certain instances, particularly 
when lower concentration range of protein was used, two rows of ill-defined bands 
were observed in the aptamer-protein complex lanes (Figure 3-12, A). The more 
concentrated (darker) shifted bands were observed towards the bottom end of the gel. 
Table 3-1: Dissociation constant (KD) values of the full length aptamers obtained 
through Biacore analysis with relevant statistics 
The values were obtained using triplicates 
 
















These bands, which represent the free probe (aptamer), ran along the same plane as 
the band in the aptamer (CSIR 2.11) alone control well. A more diffuse (“smeary”) 
area of shifted material was observed in the top part of the gel, presumably 
representing aptamer-protein complexes. The CSIR2.11-CFP-10 complexes appear 
to have migrated less than the CSIR 2.11- ESAT-6.CFP-10 dimer complexes. In the 
case where a higher protein concentration range was used (Figure 3-12, B), only 
single solid bands were observed, with no sign of hindered mobility in the aptamer-
protein complex lanes compared to the aptamer alone control. Interestingly, the 
CSIR 2.11-dimer samples migrated further than both the aptamer-CFP-10 and 
aptamer alone samples. Following several repeats with i consistent results 
(Appendix, Figure A-1), the EMSA could not be optimised. The inconsistencies 
made it difficult to attain reliable qualitative and quantitative data. Thus, the kinetic 
parameters of the aptamer-ESAT-6.CFP-10 heterodimer could not be determined 

























Figure 3-11: Confirmation of radioactive labelling of aptamer by PAGE. Aptamer 
CSIR 2.11 was labelled with 32P, analysed on denaturing and non-denaturing 8% 
PAGE gels, and viewed on a phosphorimager. The top panel (A) shows the end-
labelled CSIR 2.11 on a denaturing gel, while the bottom panel (B) shows the same 
























































































































































































































CSIR 2.11- CFP-10 complex
2nd row of bands in wells with EA10 + 
Dimer and CFP-10, respectively
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Figure 3-12: Representative gel-shift analysis of the CSIR 2.11 aptamer. 
Increasing amounts of protein (either CFP-10 or ESAT-6.CFP-10 dimer-indicated 
above wells) were mixed with 32P-end labelled CSIR 2.11. Samples were run on a 
native 8% Polyacrylamide gel. The gels were dried and exposed to a phosphor 
screen and viewed on a phosphorimager. Two sets of protein concentrations were 
studied. Phosphor images represented in A and B depict the lower and higher 
















3.5 Structural characterisation of the full length aptamers 
Given that aptamer-target interactions are attributed mainly to structural 
compatibility, characterisation of the structural features of the aptamers was 
necessary in order to delineate the structural contributions of these aptamers in target 
recognition. 
3.5.1 Primary structures 
The primary structures (sequences) of the six full length aptamers that were chosen 
for further characterisation are shown in Table 3-2. Sequence alignment using 
BioEdit Sequence Alignment Editor showed no conserved regions in the random 
region of the aptamers. There were no common motifs between the aptamers to 
which their binding functionality could be attributed. The “Plot identities” 
application of the BioEdit program revealed very little nucleotide sequence similarity 
between CSIR 2.11 and the five other aptamers (Table 3-3). The dots represent bases 
are common nucleotides between each of the aptamers and CSIR 2.11. Most of the 
dots were observed in the constant (primer) regions; which was expected.  
Aptamer name/ID Aptamer sequence






















Aptamer name/ID Aptamer sequence
Forward primer Random region Reverse primer
 
 
3.5.2 Prediction and analysis of secondary structures of full length 
aptamers using in silico methods 
Secondary structures of aptamers define which regions of the primary structure 
contribute to the overall target-binding conformation. Secondary structures of the 
anti-ESAT.CFP-10 aptamers were predicted with mfold. The program generated for 
each aptamer, either one or multiple low energy conformations into which the 
aptamer could stably fold (Figures 3-13 to 3-18). In cases where multiple low energy 
conformations were predicted, the suboptimal structures showed similar folding 
patterns in terms of stem-loops, as well as free energy values very close to that of the 
predicted MFE structure. From the structural simulations, CSIR2.11 and CSIR 2.15 
had only one predicted structure under the stated conditions, while CSIR 2.2, CSIR 
2.9, CSIR 2.19, and CSIR 2.21 had more than one (Figure 3-13). For CSIR 2.11 and 
2.19 in particular, the primer regions, predominantly the 5′ end did not seem to show 
significant contribution to secondary structures (Figures 3-13 and 3-17). 


















CSIR 2.11 Full Length ( 90-mer)
 
        
 
Figure 3-13: Potential secondary structure of aptamer CSIR 2.11 as predicted by 
mfold. Structure prediction for CSIR 2.11 yielded one minimum free energy (MFE) 
structure. Positions 1–20 and 68–90 are the primer sequences. The structure shows 
three stem-loops, with varying nucleotide lengths, which stabilize the structure of the 























      
 
Figure 3-14: Potential Secondary Structures of aptamer CSIR 2.2 as predicted by 
mfold. Structure prediction for CSIR 2.2 yielded two structures within close free 
energy range. Positions 1–20 and 68–90 are the primer sequences. The structure 
shows stem-loops, with varying nucleotide lengths, which stabilize the structure of the 
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Figure 3-15: Potential Secondary Structures of aptamer CSIR 2.9 as predicted by 
mfold. Structure prediction for CSIR 2.9 yielded four minimum free energy 
structures. Positions 1–20 and 68–90 are the primer sequences. The structure shows 
stem-loops, with varying nucleotide lengths, which stabilize the structure of the 





















Figure 3-16: Potential Secondary Structure of aptamer CSIR 2.15 as predicted by 
mfold. Structure prediction for CSIR 2.15 yielded one minimum free energy structure. 
Positions 1–20 and 68–90 are the primer sequences. The structure shows stem-loops, 
with varying nucleotide lengths, which stabilize the structure of the aptamer. The ∆G 
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Figure 3-17: Potential Secondary Structures of aptamer CSIR 2.19 as predicted by 
mfold. Structure prediction for CSIR 2.19 yielded three minimum free energy 
structures. Positions 1–20 and 68–90 are the primer sequences. The structure shows 
stem-loops, with varying nucleotide lengths, which stabilize the structure of the 




























Figure 3-18: Potential Secondary Structures of aptamer CSIR 2.21 as predicted by 
mfold. Structure prediction for CSIR 2.21 yielded three minimum free energy 
structures. Positions1–20 and 68–90 are the primer sequences. The structure shows 
stem-loops, with varying nucleotide lengths, which stabilize the structure of the 

















3.6 Rational truncation of full length aptamers based on predicted secondary 
structures 
Based on the secondary structure analyses, the nucleotides comprising the stem-loop 
combinations of the aptamer structures were hypothesized to be the key elements 
involved in target-binding. Therefore, rational truncation of CSIR 2.11 and 2.19 was 
carried out by deleting parts of the full length sequences, primarily the nucleotides in 
the constant regions. The aptamers were truncated as much as possible without 
affecting their final secondary structures. This process yielded shorter versions of the 
aptamers which maintained the overall structure of the predicted target-binding 




































                      
 
Figure 3-19: Truncation of aptamer CSIR 2.11 guided by its secondary structure. A. The 
predicted secondary structure for the original sequence of aptamer CSIR 2.11 consists of 
three stem-loops (I to III). All three stems consist of standard Watson-Crick base pairs. 
The numbers of number of base pairs in each stem are four, two, and five respectively.  
Truncation 1 (T1), in B (70-mer) resulted from removing 20 nucleotide bases in the 
direction the 5′ to 3′ (arrows, *), while the second truncation, T2, shown in C (77-mer) 
resulted from cutting out 13 nucleotide bases in the direction 3′ to 5′ (arrows, #). All the 
stem-loops, along with their assigned free energy (∆G, in kcal/mol), were retained in the 
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Figure 3-20: Truncation of aptamer CSIR 2.19 by secondary structure-guided methods. 
A. The predicted secondary structure for the original sequence of aptamer CSIR 2.19 
consists of two stem-loops (I to II). Both stems consist of standard Watson-Crick base 
pairs. The numbers of number of base pairs in each stem are five, and four, respectively.  
Truncation 1 (T1), in B (49-mer) resulted from removing 41 nucleotide bases in the 
direction the 5′ to 3′ (arrows, *), while the second truncation, T2, shown in C (77-mer) 
resulted from cutting out 13 nucleotide bases in the direction 3′ to 5′ (arrows, #). Both 
stem-loops, along with their assigned free energy values (∆G, in kcal/mol), were retained 
















3.7 Conformational energy landscape analysis of full length aptamers and 
truncated derivatives 
3.7.1 In silico analysis of folding behaviour of CSIR 2.11 and 2.19: 
energetics and folding kinetics 
Conformational energy landscapes of CSIR 2.11 and CSIR 2.19 were simulated using 
the Barriers program of the Vienna RNA Web server. Barrier trees and folding 
kinetics simulations of aptamers CSIR 2.11 and CSIR 2.19 and their truncated 
derivatives are illustrated (Figures 3-21 to 3-26). While the program computes folding 
landscapes over millions of possible conformations for one sequence, for simplicity, 
only the 50 lowest local minima are shown in the barrier tree for each aptamer. The 
energy barriers between these minima are presented above each leaf. Folding kinetics 
simulations were computed by treekin using the 50 local minima (represented on each 
tree) as macro-states for the coarse-grained dynamics simulations. The treekin output 
is represented as folding kinetics graphs (Figures 3-21 to 3-26—on the right hand side 
of each barrier tree). These graphs show the fraction of folding pathways for each 
aptamer sequence en route to the MFE structure, plotted on a logarithmic time scale. 
The time scale is represented in arbitrary units, referred to as “time steps”.  The 
graphs portray the population density of the basins of attraction of the local minima as 
a function of time. This gives an indication of which structures are likely to compete 
with the MFE and possibly hinder the interaction of the target with the MFE, should 
the MFE not be reached within a biologically reasonable time frame. The folding 
process was started in the open chain state equivalent (indicated in black on the 
graphs for each of the aptamers analysed), and run until thermodynamic equilibrium 
distribution was reached within the user-specified time-frame.  
With the folding process simulations presented in herein, the focus was not on the 
time it takes to reach a thermodynamically stable equilibrium distribution, but rather 
the refolding time from a selected start structure (representing the denatured or open 
chain structure) to the MFE structure (the global minimum, denoted by the number 1 
















3.7.2 Conformational energy landscapes of full length and truncated 
derivatives of CSIR 2.11 
For the CSIR 2.11 90-mer aptamer, the tree shows three distinct subtrees, which 
represent the three most dominant folding pathways (Figure 3-21). The basins of 
attraction (seen in the three subtrees) converge into structures 1, 4 and 33, in 
respective order of increasing free energy. Structures 1, 4 and 33 are the lowest 
hanging minima in each basin of attraction or subtree. The subtree that is the most 
occupied (i.e. with the most leaves), and the more likely kinetically preferred, is the 
one containing the local minimum 4 and not the MFE (1) as would have been 
expected. However, once the MFE is reached, it is not likely for aptamer CSIR 2.11 to 
switch between conformations in the two subtrees. This is due to the fact that in terms 
of barrier heights, the energy landscape portrays a downhill walk from 4 to 1, while 
the opposite direction is something of an uphill climb.  
Also shown in Figure 3-21 (B) is a graphical representation of the folding kinetics of 
the aptamer as determined by the treekin simulations. As indicated, the graph shows 
the fraction of folding pathways leading to the MFE, and the population density of the 
basins of attraction as a function of time. For the 90-mer CSIR 2.11 tree, the 
denatured or open-chain conformation was represented by local minimum 50 (the 
structure in the ensemble with a ∆G value closest to zero), which is directly connected 
to local minima 44 and 33 via energy barriers of 0.4 and 0.5kcal/mol, respectively. 
The simulation showed an initial rapid decline in the population of local minimum 50 
(the “open chain”); from 100 percent to approximately zero before 1000 time-steps. 
As expected (based on the barrier tree), local minima 33 and 44, both of which belong 
to the same basin of attraction as local minima 50, were dominant in the beginning of 
the refolding process. The two were later followed by local minima 4 and 8, after 
which the simulation ended (within the set time frame of ~ 1e+10) with the MFE 
coming up to less than 20% population density. Other local minima that may have 
existed in the population are not shown in the graph, as they were populated at rates 

















The 77-mer CSIR 2.11 showed a similar folding pattern to that of the 90-mer, both on 
the tree and associated kinetics, with the MFE being reached only after time steps 
1e+03 (Figure 3- 22). The basins of attraction, as seen in the three subtrees, converge 
into structures 1, 5 and 22, in respective order of increasing free energy. The most 
populated subtree contains local minima 5, 6, and 7, which may act as kinetic traps 
that could hinder the folding path to the MFE.  However, the thermodynamic cost of 
switching between conformations in this subtree and the one containing the MFE is 
high (as indicated by the barrier height). Furthermore, the MFE population of the 77-
mer is slightly higher than that of the 90-mer and the 70-mer. 
The 70-mer showed a different folding pattern to 90-mer and 77-mer, with the subtree 
that is most populated containing the MFE and the population of the MFE peaking 
earlier, at time step 1e+02 (Figure 4-23). The basins of attraction, as seen in the three 
subtrees, converge into structures 1, 5, 36 and 46, in respective order of increasing 
free energy. These structures are the lowest h nging minima. The subtree that is the 
most occupied and the more likely kinetically preferred contains the MFE. The 
significant local minima, such as 5, 8, 36 and 46 are not likely to act as kinetic traps.  
Local minimum 2 appears to be a strong competitor of the MFE, as the two structures 
show up and reach almost equal maximum density around the same time. This 
suggests a likely conformation switch between the two structures. However, the MFE 































Figure 3-21: Barrier tree and folding kinetics of the 90-mer CSIR 2.11. A. The barrier 
tree the lower energy portion of the conformational landscape.  The leaves (1 to 50) of 
the tree represent the 50 lowest local minima numbered by their energy, and the 
numbers labelling the branches are the barrier heights denoting the free energy 
differences between the local minima) in kilocalories/mol. The saddle points (nodes) 
are the energetically highest points on a folding path between any two local minima. 
The basins of attraction (seen in the three subtrees) converge into structures 1, 4 and 
33, in respective order of increasing free energy. B. Folding kinetics of CSIR 2.11 from 
the open chain structure (computed by the treekin program of the Vienna RNA 
Barriers). The plot shows the population density of meta-stable states along a simulated 
folding path beginning from the open chain (or the structure with the highest free 
energy value, in this case structure 50, black line), and eventually reaching the MFE 
structure. The population density of the initial state (structure 50) quickly declines, 
reaching 50% at time step 1e+ 00, and later 0% by time 1e+03. Local minima  44 and 
33 appear more dominant at the beginning of the refolding process, reaching 25 and 35 
% density at time 1e+00, respectively. The global minimum (MFE—structure 1) 
reaches its highest density later at time step 1e+05, and stabilizes at a density of about 
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Figure 3-22: Barrier tree and folding kinetics of the 77-mer CSIR 2.11. The barrier 
tree is shown in A. The numbers 1 to 50 represent the 50 lowest local minima 
numbered by their energy, and the numbers labelling the branches are the barrier 
heights denoting the free energy differences between the local minima) in 
kilocalories/mole. The saddle points (nodes) are the energetically highest points on a 
folding path between any two local minima. There are two distinct folding pathways, 
with the basins of attraction (seen in the two subtrees) converging into structures 1, 
and then 5, 22, and 24 in respective order of increasing free energy (5, 22, and 24 are 
found in the same subtree). B. folding kinetics of CSIR 2.11 77-mer from the open 
chain structure (computed by the treekin program of the Vienna RNA Barriers). The 
plot shows the population density of meta-stable states along a simulated folding path 
beginning from the open chain (or the structure with the highest free energy value, in 
this case structure 49, black line) and eventually reaching the MFE conformation. The 
population density of the initial state (structure 49) quickly declines, reaching 50% at 
time step 1e+ 00, and later 0% before 1e+03. Local minima  22 appears more 
dominant at the beginning of the refolding process, reaching 60 % density by time 
1e+00, quickly followed by 24, and then local minima 5, 6 and 7 which are found in 
the same basin of attraction. Local minima 2 and 3 start to show up in the population 
around the same time as the global minimum (MFE—structure 1), which reaches its 
highest density and dominance later just after time step 1e+04, and stabilizes at a 





























Figure 3-23: Barrier tree and folding kinetics of the 70-mer CSIR 2.11. The barrier 
tree is shown in A. The numbers 1 to 50 represent the 50 lowest local minima 
numbered by their energy, and the numbers labelling the branches are the barrier 
heights denoting the free energy differences between the local minima) in 
kilocalories/mole. The saddle points (nodes) are the energetically highest points on a 
folding path between any two local minima. There are two distinct folding pathways, 
represented by two basins of attraction: the one converging into structure 1 and that 
containing structures 36 and 46. B. Folding kinetics of CSIR 2.11 70-mer from the 
open chain structure (computed by the treekin program of the Vienna RNA Barriers). 
The plot shows the population density of meta-stable states along a simulated folding 
path beginning from the open chain (or the structure with the highest free energy 
value, in this case structure 50, black line) and eventually reaching the MFE 
conformation. The population density of the initial state (structure 50—black) quickly 
declines, reaching 50% at time step 1e+ 00, and later 0% before 1e+03. Local minima 
36 appears more dominant at the beginning of the refolding process, reaching almost 
40 % density by time 1e+00, quickly followed by 46, 35, and 5 and 8 which are found 
in the same basin of attraction. The global minimum (MFE—structure 1) makes up 
part of the population at time step 1e+00 already, competing with structures 5, 8, and 
2, and peaks just after time step 1e+02, and stabilizes at a density of over 20%, with 
















3.7.3 Conformational energy landscapes of full length and truncated 
derivatives of CSIR 2.19 
For the 90-mer CSIR 2.19, the major basins of attraction converge into structures 1, 2, 
and 16 in respective order of increasing free energy (Figure 3-24). The subtree that is 
the most occupied and the more likely kinetically preferred is the one containing the 
MFE (1). This is a more favourable picture of the folding energy surface. Local 
minimum 16 starts out as the dominant structure, with the highest occupancy of over 
60%. Local minimum 2 is a strong competitor of the MFE, which again, implies a 
likely conformation switch between the two structures, more so because the two have 
equal ∆G values. However the percentage occupancy of the MFE peaks earlier than 
that of structure 2. This suggests that the MFE will have some time to interact with 
the target before structure 2 has a chance compete. 
The 49-mer CSIR 2.19 aptamer showed similar folding kinetics to that of the 90-mer, 
but with a higher MFE population of almost double that of the 90-mer (Figure 3-25). 
The basins of attraction converge more prominently into structures 1, 2, 3, 12 and 31, 
in respective order of increasing free energy. Structure 1 and 2 are strong 
thermodynamic competitors as depicted on the tree and the folding kinetics graph. 
However, the percentage occupancy of structure 2 only reaches about half that of 1 
after time step 1e+ 03. This suggests that structure 1 (MFE) is the more kinetically 
preferred structure. The two structures have maximum percentage occupancy in the 
same range—an expected outcome since they have almost equal free energy at 
thermodynamic equilibrium, even though they belong to different basins of attraction. 
The 77-mer CSIR 2.19-mer showed favourable kinetics, with the most occupied 
subtree containing the MFE (Figure 3-26). The MFE population of the 77-mer 
aptamer is higher than that of the 90-mer and 49-mer and is reached slightly earlier, 
before time step 1e+ 02. The MFE and local minimum 2 are found in different basins 
in this case. This favours the MFE in that once formed, the aptamer is not likely to 
switch to local minima 2 conformation because of the high barrier it will have to 




























Figure 3-24: Barrier tree and folding kinetics of the 90-mer CSIR 2.19. The barrier tree is 
shown in A. The numbers 1 to 50 represent the 50 lowest local minima numbered by their 
energy, and the numbers labelling the branches are the barrier heights denoting the free 
energy differences between the local minima) in kilocalories/mole. The saddle points (nodes) 
are the energetically highest points on a folding path between any two local minima. There 
are three distinct folding pathways, with the basins of attraction (seen in the three subtrees) 
converging into structures 1, 2, and 16 in respective order of increasing free energy. B. 
folding kinetics of CSIR 2.19 90-mer from the open chain structure (computed by the treekin 
program of the Vienna RNA Barriers). The plot shows the population density of meta-stable 
states along a simulated folding path beginning from the open chain (or the structure with the 
highest free energy value, in this case structure 47, black line) and eventually reaching the 
MFE conformation. The population density of the initial state (structure 47—black) quickly 
declines, reaching 50% at time step 1e+00, and later 0% before 1e+03. Local minima  16 
appears more dominant at the beginning of the refolding process, reaching 60 % density by 
time 1e+00, quickly followed by the global minimum (MFE—structure 1)  and local 
minimum 2, which is a strong competitor of structure 1 . Structure 1 peaks earlier, structure 2 
catches up shortly after 1, and the two share similar density—an expected outcome since they 
have almost equal free energy at thermodynamic equilibrium, even though they belong to 




























Figure 3-25: Barrier tree and folding kinetics of the 49-mer CSIR 2.19.  The barrier tree is 
shown in A. The numbers 1 to 50 represent the 50 lowest local minima numbered by their 
energy, and the numbers labelling the branches are the barrier heights denoting the free 
energy differences between the local minima) in kilocalories/mole. The saddle points (nodes) 
are the energetically highest points on a folding path between any two local minima. There 
are three distinct folding pathways, with the basins of attraction (seen in the three subtrees) 
converging into structures 1 and 3 (same basin), then 2, 12, and 31, in respective order of 
increasing free energy. B. folding kinetics of the 49-mer CSIR 2.19 from the open chain 
structure (computed by the treekin program of the Vienna RNA Barriers). The plot shows the 
population density of meta-stable states along a simulated folding path beginning from the 
open chain (or the structure with the highest free energy value, in this case structure 43, black 
line), and eventually reaching the MFE conformation. The population density of the initial 
state (structure 43, at ∆G~0) quickly declines, reaches 50% at time step 1e+ 00, and later 
drops to 0% before 1e+03. Local minima  31 appears more dominant at the beginning of the 
refolding process, reaching over 40 % density by time 1e+00, quickly followed by 12, 3, the 
global minimum (MFE—structure 1) and local minimum 2, which is also a strong competitor 
of structure 1 . Structure 1 peaks earlier than structure 2, and the two share similar density—
an expected outcome since they have almost equal free energy at thermodynamic equilibrium, 




























Figure 3-26: Barrier tree and folding kinetics of the 77-mer CSIR 2.19. The barrier tree 
is shown in A. The numbers 1 to 50 represent the 50 lowest local minima numbered by 
their energy, and the numbers labelling the branches are the barrier heights denoting the 
free energy differences between the local minima) in kilocalories/mole. The saddle 
points (nodes) are the energetically highest points on a folding path between any two 
local minima. There are two distinct folding pathways, with the basins of attraction 
(seen in the two subtrees) converging into structures 1 (with 3, 4, 5 and 6 in the same 
basin) and 2 (different basin), in respective order of increasing free energy. B. Folding 
kinetics of CSIR 2.19 77-mer from the open chain structure (computed by the treekin 
program of the Vienna RNA Barriers). The plot shows the population density of meta-
stable states along a simulated folding path beginning from the open chain (or the 
structure with the highest free energy value, in this case structure 50, black line), and 
eventually reaching the MFE conformation. The population density of the initial state 
(structure 50) quickly declines, reaching 50% at time step 1e+ 00, and later 0% before 
1e+03. The global minimum (MFE—structure 1) dominates at the beginning of the 
refolding process, reaching over 40 % density by time 1e+02. This is followed by 5, 6, 
















3.8 Validation of chemically synthesised truncated aptamers by non-denaturing 
PAGE 
The sequences of the truncated derivatives of CSIR 2.11 and 2.19 were rationally 
designed based on secondary structure simulations and analyses. The sequences of these 
aptamers, along with those of the full length parents were sent to IDT to be chemically 
synthesised on a large scale. The chemically synthesised aptamers were 5′-biotin-
modified to enable detection in the Enzyme Linked Oligonucleotide Assay (ELONA). 
The purity and apparent size of the aptamers were analysed by non-denaturing PAGE 


















Figure 3-27: Non-denaturing PAGE analysis comparing the mobilities of the full length 
and truncated aptamers. Full length ssDNA aptamers CSIR 2.11 and 2.19 are compared 
to their respective truncations of varying length. The lanes were loaded from the 
smallest to the largest sequence for each aptamer. Lanes 2 to 4 contain the 70-mer, 77-
mer, 90-mer of CSIR 2.11 and lanes 6 to 7- contain the 49-mer, 77-mer, and the 90-mer 
of CSIR 2.19 respectively.  The mobilities for the truncations and full lengths are as 
expected, (showing decreasing mobility with increase in size). The aptamers are at 
around the expected sizes; between 75 and 100bp for the full length aptamers, and the 
truncated derivatives run slightly lower than the full length sequences.  It is important to 
note that the ladder used is double stranded and thus does not allow for accurate size 
















3.9 Binding of the truncated aptamers compared to the full length  
To determine the binding of the truncated aptamers in comparison with that of their full 
length parent sequences, ELONAs were performed.  The expectation here was two-fold. 
Firstly that having eliminated non-essential bases from the aptamer sequences, the 
truncated derivatives would bind the same as the full length aptamers. Alternatively, if 
essential bases, which were not predicted as essential by mfold, were eliminated, the 
truncated versions would show inferior binding to that of the full length aptamers. 
Secondly, the outcome would also provide experimental data to support the inferences 
made from the folding dynamics analyses, which predicted that the truncated aptamers 
would likely make for more favourable binders than the full length aptamers. 
To answer these questions, ELONAs were set up with both the full length and the 
truncated aptamers and their relevant controls under the same conditions. The data 
presented herein for each aptamer are from two independent experiments, with all 
reactions performed in triplicate. The data was normalised to the full length aptamer 
plus the CFP-10 monomer absorbance, i.e. the mean relative binding of the full length 
(90-mer) + CFP-10 was set to 1. Comparative analyses of the relative binding values of 
the full length and truncated aptamers are shown for aptamers CSIR 2.11 and 2.19, 
respectively (Figures 3-28 and 3-29). As expected, the full length (90-mer) + CFP-10 
show significantly higher relative binding than the CFP-10 alone controls (* P-value 
<0.001). The signal for the truncated aptamers+ CFP-10 was significantly higher 
compared to the CFP-10 only control (* P-value <0.001). This indicates that the 
truncated aptamers retained their binding functionality. Similarly, the truncated 
aptamers were able to detect the ESAT-6.CFP-10 heterodimer (Appendix, Figures A-2 
and A-3). When comparing the relative binding of the truncated aptamers with that of 


















Figure 3-28: Relative binding of CSIR 2.11 full length and truncated aptamers to CFP-
10 assessed by ELONA. Relative binding of the biotin-labelled aptamers to the target 
proteins was measured by streptavidin-HRP-catalysed reactions, detected with TMB 
substrate, and read as absorbance values at 450nm. The binding of the truncated 
aptamers is represented relative to that of the full length. Each data point represents 
combined triplicate values from two independent experiments; normalised against the 
90-mer + CFP-10 data points. The error bars represent the standard deviation. Both the 
full length aptamer+CFP-10 and truncated aptamer+CFP-10 combinations were 
significantly higher (* P-value <0.001) than the CFP-10 alone and aptamer alone (no 
protein) controls. The truncated aptamers bound to the CFP-10 monomer with affinity 
values comparable to those of the original 90-mer aptamer, without significant 
differences. The truncated aptamers bound to the CFP-10 monomer with absorbance 




















Figure 3-29: Relative binding of CSIR 2.19 full length and truncated aptamers to CFP-
10 assessed by ELONA. Relative binding of the biotin- labelled aptamers to the target 
proteins was measured by streptavidin-HRP-catalysed reactions, detected with TMB 
substrate, and read as absorbance values at 450nm. The binding of the truncated 
aptamers is represented relative to that of the full length. Each data point represents 
combined triplicate values from two independent experiments; each normalised against 
the 90-mer + CFP-10 data points. The error bars represent the standard deviation. Both 
the full length aptamer+CFP-10 and truncated aptamer+CFP-10 combinations were 
significantly higher (* P-value <0.001) than the CFP-10 alone and aptamer alone (no 
protein) controls. The truncated aptamers bound to the CFP-10 monomer with affinity 
values comparable to those of the original 90-mer aptamer, without significant 
differences. The truncated aptamers bound to the CFP-10 monomer with absorbance 


















To recapitulate, this study investigated the structural and the functional properties of six 
anti-ESAT-6.CFP-10 aptamers, which were previously isolated by our research group 
and recently published (Rotherham et al 2012). Furthermore, this study explored the post-
SELEX optimisation of two of these aptamers, namely CSIR 2.11 and 2.19. The binding 
affinities of six full length aptamers to the CFP-10 monomer were examined by SPR 
technology. Five of the six aptamers showed tight binding to CFP-10 with KD values as 
low as 1.6 nM. One of the aptamers, CSIR 2.9, did not show concentration-dependent 
binding and its kinetics could not be derived using the SPR technology. EMSA was used 
to determine the kinetic interactions between CSIR 2.11 and the ESAT-6.CFP-10 
heterodimer, however the results thereof were inconsistent and thus kinetic parameters 
could not be estimated. The structural properties of the aptamers were predicted by 
theoretical computational methods, using Zucker’s mfold and the Vienna RNA package 
programs. These programs allowed for the prediction of secondary structure traits of the 
aptamers, such as the MFE structure and associated Gibbs free energy (ΔG), as well as 
folding energy landscapes. Predicted secondary structure features were used to forecast 
the target-binding motifs of the aptamers, and inform the post-SELEX optimisation of 
two of the aptamers by rational truncation. Fittingly, full length aptamer sequences were 
truncated to shorter derivatives which retained the predicted target-binding parts. The 
binding affinity of truncated aptamers was compared to that of their full length parent 
sequences through ELONA. The truncated aptamers showed comparable binding to the 



















4.1 Expression and purification of ESAT-6 and CFP-10 
Expression and purification of histidine-tagged ESAT-6 and CFP-10 were successfully 
achieved, as confirmed by SDS-PAGE and immunoblotting analysis. During expression, 
ESAT-6 is known to enter inclusion bodies when induced at 37°C (Renshaw et al., 2002). 
Therefore, to help increase its solubility, the ESAT-6 bacterial cultures were grown at 
25°C (Chaudhary et al., 2005, Kulshrestha et al., 2005). This allowed for the localisation 
of ESAT-6 in the soluble fraction rather than in inclusion bodies (Rotherham et al., 
2012). Furthermore, the use of a chaotropic agent, such as urea, in the purification 
process helped improve the solubility of ESAT-6 (Rotherham et al., 2012). 
Purification of ESAT-6 and CFP-10 was achieved using IMAC; a widely used method 
which involves capturing proteins containing peptid  affinity tags on an immobilised 
metal-based matrix (Bornhorst and Falke, 2000, Ward and Swiatek, 2009). The technique 
is based on the interactions between a transition metal ion, in our case, Nickel (Ni2+) and 
the amino acid side chains on the Histidine tag (Bornhorst and Falke, 2000). This method 
allowed for rapid protein purification and is known to potentially achieve purities of up to 
95% in high yield (Bornhorst and Falke, 2000, Ward and Swiatek, 2009). However, the 
yields obtained in the current study were very low, in comparison to previous studies 
using similar protocols (Bornhorst and Falke, 2000, Renshaw et al., 2002, Ward and 
Swiatek, 2009). The low yields could be attributed to a number of technical factors 
during the expression and purification process. These unfavourable factors may have 
resulted from the culturing conditions, the protein extraction process (Ward and Swiatek, 
2009), the purification method (Sivashanmugam et al., 2009), or a combination of these. 
Although some great advances have been made in the art of protein expression over the 
years, the production of functional eukaryotic proteins in E.coli at high levels still has 
some challenges (Sivashanmugam et al., 2009). These challenges range from the 
structural properties of the gene sequence to be expressed, the stability and translational 
















cell proteases (Sivashanmugam et al., 2009). To address some of these, a number of 
solutions can be tailored for the particular protein to be expressed. One approach could be 
optimising growth conditions, which are mostly target-dependent and cannot for the most 
part be universalised (Sivashanmugam et al., 2009). Flaws in the culturing conditions 
such as limited oxygen availability and increased carbon dioxide, which affects the pH of 
the growth medium, and plasmid loss, can adversely affect the protein expression process 
(Sivashanmugam et al., 2009). These problems often cause low and in some case no 
protein production (Sivashanmugam et al., 2009). To circumvent some of these, culture 
growth temperatures can be changed, as was done for ESAT-6 in previous studies 
(Renshaw et al., 2002). Also, instead of inducing protein expression at OD600 of 0.6, 
induction could be attempted at an intermediate value such as in the middle of the growth 
phase, to ensure high-level protein expression (Sivashanmugam et al., 2009). 
For purification purposes, while the IMAC method is generally successful (Ward and 
Swiatek, 2009), it is reported that the method may fall short, particularly in the case of 
tagged proteins which are expressed at low levels or for the preparation of highly 
homogeneous protein samples (Bornhorst and Falke, 2000). Moreover, purity is also a 
concern. The non-specific binding of proteins to the IMAC-based columns is cited a 
major disadvantage, more so when the tagged protein is not expressed at high levels 
(Bornhorst and Falke, 2000). This suggests that there would likely be other proteins in the 
“purified protein” sample which may be included in the quantitation process, thus giving 
an overestimate of the yield of the protein of interest. These overestimations could affect 
the outcome of downstream functional assays. However, this limitation can be avoided by 
using the same batch of protein whose estimated concentration will be the assumed 
“standard” and having all other concentration estimations be derived from that standard. 
For the proteins expressed in the current study, however, controlling for batch-to-batch 
variation would have been tricky as the yields from each expression were much lower 
















Therefore, to circumvent the factors discussed above, and to avoid the high cost 
implications of reagents, consumables and time that came with the required multiple 
expression and purification repeats, we opted to purchase large-scale produced, HPLC-
purified protein for use in further experimentation and functional assays. The purchased 
ESAT-6 and CFP-10 were used for the in vitro production of the ESAT-6.CFP-10 
heterodimer complex. The formation of the heterodimer was confirmed by native PAGE 
and showed similar migration patterns to those previously observed by (Rotherham et al., 
2012).  
4.2 In-house production of ssDNA aptamers 
Plasmid DNA was successfully prepared and purified, and subsequently used in PCR 
amplification assays to produce dsDNA using previously described protocols (Avci-Adali 
et al., 2009). Optimisation steps were carried out in order to maximize the yield and 
purity of the PCR product; and the conditions outlined in the methods section were found 
to be optimal. Lambda exonuclease-digestion of dsDNA was found to be effective in 
generating ssDNA. The lambda exonuclease enzyme selectively digests the 5′- 
phosphorylated strand of dsDNA, leaving the complementary single strand intact for use 
in functional assays (Avci-Adali et al., 2009), This method is known to be among the 
most effective for this purpose, when compared to other techniques such as denaturing 
urea-polyacrylamide gel, asymmetric PCR, and streptavidin-coated beads-biotin 
separation (Avci-Adali et al., 2009). For instance, the product from the asymmetric PCR 
has to be purified by nondenaturing electrophoresis and eluted from the gel (Avci-Adali 
et al., 2009). This process is not only time consuming, but results in low yields 
(Marimuthu et al., 2012). Furthermore, the alkaline conditions streptavidin-coated beads-
biotin separation method may lead to loss of the tertiary structure of the ssDNA and 
consequently compromise the target-binding function of the aptamer. While exonuclease 
digestion provided a rapid way of producing ssDNA, the maximum yields obtained in the 
current study were about 30% lower in comparison to previous studies gel (Avci-Adali et 
















assays, high amounts of ssDNA were required, which meant repeated steps of PCR and 
exonuclease digestions would have to be conducted. This would be time-consuming and 
costly. Thus, large-scale chemical synthesis of the aptamers was opted for instead. 
4.3 Characterisation of full length aptamers 
4.3.1 Binding Kinetics of full length aptamers as determined by SPR 
The molecular interactions between full length aptamers and the CFP-10 monomer were 
characterised by SPR as previously described (Joss et al., 1998, Kimple et al., 2010). The 
aptamers in this study showed high affinity to CFP-10 and generally displayed 
concentration-dependent binding. It is important to note that these binding properties 
refer to immobilised-ligand binding properties, which may be different from those in 
free-ligand assays, depending on the analyte-ligand pair in question (Win et al., 2006). 
Also, the coupling method used to immobilise the ligand can influence the outcome of 
the experiment (Joss et al., 1998, Kimple et al., 2010). Random direct coupling methods 
such as amine coupling the ligand to the dextran surface of the chip, which was used in 
this study, may introduce surface-imposed heterogeneity by reacting with residues in or 
near the recognition site (Joss et al., 1998, Kimple et al., 2010). This effect may distort 
the binding properties of the ligand, and can be minimised by capturing the ligand using 
antibodies, or streptavidin–biotin interactions (Joss et al., 1998, Kimple et al., 2010). 
However, the amine coupling of CFP-10 to the SPR sensor chip did not seem to 
adversely affect binding to the aptamers in this study.  
The kinetics data obtained in the current study indicate tight binding of the aptamers to 
CFP-10, with KD values in the nanomolar ranges, which are within the expected range for 
aptamers and consistent with earlier findings by others (Chiu, 2009, Famulok et al., 2007, 
Pendergrast et al., 2005, Proske et al., 2005). Of the six aptamers studied, CSIR 2.19 
showed the best binding kinetics, with the lowest KD of 1.6 nM. The low KD values are 
an indication of high affinity to the target and support the feasibility of using these 
















CSIR 2.11, which previously showed the highest absorbance reading using ELONA 
(Rotherham et al., 2012), did not exhibit the lowest KD when SPR was used. This 
discrepancy could be attributed to the technical sophistication of the SPR technology 
compared to that of the ELONA. SPR assays give better concentration-dependent 
responses and have better sensitivity than ELISA (Lee et al., 2008). This is primarily 
because the SPR instrument records binding events in real time in contrast to the end-
point binding result in the ELONA (Luzi et al., 2003, Nguyen et al., 2009). 
Kinetic data is generally interpreted according to the model of analysis used, and the 
choice of model is dependent on the nature of the experiment. The kinetic parameters of 
the aptamers evaluated in this study were obtained using the Langmuir model assuming 
1:1 binding. This model is the simplest and most widely used model (Gopinath, 2010, 
Joss et al., 1998). Although the model is not considered a precise or perfect 
representation of what happens on the chip surface (Gopinath, 2010, Joss et al., 1998) , 
using this model to perform kinetic ranking of different analytes binding to the same 
ligand but from data which do not represent homogenous binding is considered justifiable 
(Gopinath, 2010, Joss et al., 1998). Therefore, the apparent dissociation constants 
determined this way are sufficient for most purposes (Gopinath, 2010, Joss et al., 1998). 
For kinetic evaluations in the current study, the results were found to be within 
acceptable ranges of the relevant statistical measures. One such statistical measure is the 
Chi2 value, which measures the “closeness or goodness of fit” of experimental data to the 
theoretical model used to analyse data (Gopinath, 2010, Joss et al., 1998, Tombelli et al., 
2005, Win et al., 2006). It is recommended that for good fitting data, the Chi2 value 
should be of the same order of magnitude as the noise signal (Biacore, 1997). The Chi2 
values obtained in the current study were in the lower single digits while the noise signal 
was in the lower double digits; on average, no more than 20 RU. To further support the 
reliability of the kinetics data obtained in this study, the KD values ought to be within the 
expected range for the type of molecular interaction being assessed (Li et al., 2006, Luzi 
















particular, these values are generally within lower nanomolar ranges (Li et al., 2006, Luzi 
et al., 2003, Potyrailo et al., 1998, Tombelli et al., 2005, Win et al., 2006). Thus, the 
kinetic data obtained in this study are considered satisfactory.  
On the other hand, CSIR 2.9 neither displayed concentration-dependent binding nor 
kinetic parameters that fit the Langmuir 1:1 model used for analysis. SPR-based kinetic 
evaluations can be affected by several factors including the purity of reagents, the 
immobilisation procedure and level, ligand activity, flow rate and analyte concentration 
range (Biacore, 1997, Gopinath, 2010, Joss et al., 1998). The problem with respect to the 
CSIR 2.9 kinetics could not be attributed to the activity of the ligand (CFP-10), as the 
aptamers that were injected over the same ligand surface following aptamer CSIR 2.9 and 
subsequent regeneration still showed concentration-dependent binding and good kinetic 
parameters. It could be that the conditions in which the binding reactions were taking 
place, which suited the other five aptamers, may not have been favourable for CSIR 2.9. 
Alternatively, considering that the SPR is a more sensitive (Lee et al., 2008) and possibly 
more accurate (Biacore, 1997, Gopinath, 2010, Joss et al., 1998) technique than the 
ELONA, the CSIR 2.9 aptamer may not be a high affinity binder as was previously 
suggested by the initial ELONA screening assays performed by (Rotherham et al., 2012). 
Altogether, characterisation and quantification of the interactions between the anti-
ESAT-6.CFP-10 aptamers and the CFP-10 protein were achieved using SPR technology 
in the current study. The aptamers showed KD values in the nanomolar range, indicating 
high affinity to the CFP-10 protein. Accordingly, the five aptamers whose kinetics were 
determined in the current study, particularly CSIR 2.19, are good candidates for use as 
detection probes for CFP-10 proteins secreted by MTB. Although, including controls 
such as an unrelated aptamer sequence and assessing binding to CFP-10, and 
immobilising an unrelated protein to the sensor chip was necessary in order to 
conclusively confirm aptamer selectivity to the target proteins (Dupont et al., 2010, Lee 
















4.3.2 Evaluation of Binding affinity of aptamer CSIR 2.11 by EMSA 
EMSA is another technique that can be used to characterise molecular interactions 
between nucleic acids ligands and cognate proteins. To do this, the electrophoretic 
mobility of nucleic acid-protein complexes is measured relative to that of free (unbound) 
nucleic acids (Hellman and Fried, 2007, Demarse et al., 2009). The method is based on 
the premise that nucleic acid-protein complexes migrate slower than the corresponding 
free nucleic acids. The current study employed the EMSA approach with a view to 
examine the binding of CSIR 2.11 to the ESAT-6.CFP-10 dimer and to the CFP-10 
monomer, respectively. CSIR 2.11 was successfully labelled with radioactive nucleotides 
to enable the visualisation and quantification of aptamer-protein interactions. However, 
the results were inconclusive.   
When lower protein concentrations (250 to 1000 nM) were used, two rows of bands were 
observed in the aptamer-protein lanes, suggesting modest mobility shift. Furthermore, the 
CSIR 2.11-CFP-10 complexes migrated less than the CSIR 2.11-ESAT-6.CFP-10 dimer 
complexes, in the same way that the CFP-10 monomer migrated less than the dimer 
under non-denaturing PAGE conditions as previously reported (Rotherham et al., 2012). 
Typically, nucleic acid mobility and the amount of  free or unbound nucleic acid usually 
decrease with an increas  in the concentration of the cognate protein (Hellman and Fried, 
2007). However, this trend was not apparent in the current study when using the lower 
protein concentration range. In contrast, when higher protein concentrations (1 μM to 10 
μM) were used, only single bands were observed in the aptamer-protein lanes, and the 
shift was in the opposite direction to what was expected. The CSIR 2.11-ESAT-6.CFP-10 
dimer complexes appeared to have migrated further than the CSIR 2.11 only control. This 
outcome cannot be pinned down to a single factor as the results varied considerably 
across experimental repeats.  
Nonetheless, an EMSA shift is primarily influenced by three key factors: molecular 
















(Alves and Cunha, 2012, Hellman and Fried, 2007). During electrophoresis, the 
negatively charged nucleic acid migrates towards the anode. The extent of this migration 
is proportional to the molecular weight of the nucleic acid (Alves and Cunha, 2012, 
Hellman and Fried, 2007), which is related to nucleic acid chain length (Hellman and 
Fried, 2007). In addition, the net charge of the nucleic acid-protein complex, which is 
also affected by the protein charge, plays a role in mobility (Alves and Cunha, 2012, 
Hellman and Fried, 2007). If the protein charge is highly negative (as would be the case 
when its isoelectric point is lower than the pH of the electrophoresis buffer), the protein is 
likely to move towards the anode  and may cause the nucleic acid-protein complexes to 
migrate very close to or further than the nucleic acid (Hellman and Fried, 2007). In terms 
of nucleic acid topology, if the binding of a protein does not induce any considerable 
bend on the nucleic acid, the conformational contribution of that protein to mobility 
retardation would be minimal (Hellman and Fried, 2007). These factors may have 
independently or collectively contributed to the atypical results observed in the current 
study. Interestingly, the binding of a protein to a nucleic acid has been previously shown 
to accelerate rather than hinder mobility (Hellman and Fried, 2007). This outcome was 
observed in a study by (Sandman et al., 1990), where the protein induced nucleic acid 
condensation of a relatively large linear DNA. In this case, the conformational change of 
the DNA was a stronger factor than the overall molecular weight increase, which in turn 
caused acceleration rather than a decrease in DNA mobility (Hellman and Fried, 2007). 
Although EMSA is considered a relatively fast, effective and highly sensitive technique 
which can be used to characterise molecular interactions (Chorley et al., 2008, Hellman 
and Fried, 2007); it has limitations. Apart from the samples not being at chemical 
equilibrium during electrophoresis (Hellman and Fried, 2007), the mobility of nucleic 
acid-protein complexes is influenced by several factors other than the size and 
concentration of the protein (Chorley et al., 2008, Hellman and Fried, 2007), such as 
those discussed above. These factors introduce multiple variables that influence the 
















(Alves and Cunha, 2012, Demarse et al., 2009, Hellman and Fried, 2007), which can be 
time-consuming and challenging (Chorley et al., 2008). Having employed the 
recommended electrophoretic conditions such as gel type, buffer conditions, and complex 
stabilising factors (Hellman and Fried, 2007, Laniel et al., 2001), the EMSA protocol in 
the current study could not be optimised.  Consequently, the strength of the aptamer-
target interactions and associated kinetic parameters could not be determined using this 
method 
4.4 Structural features of the aptamers and their predicted contribution to 
function 
Secondary structures of the anti-ESAT-6.CFP-10 aptamers were predicted using 
theoretical algorithms. Zucker’s mfold was used to estimate the MFE for each aptamer. 
These structures provided a geometric and thermodynamic framework for potential 
tertiary structures (Flamm  et al., 2004). In nucleic acid folding, double stranded helices 
typically form before the tertiary contacts of nucleic acids complete the formation of the 
three-dimensional structure (Flamm  et al., 2004). Furthermore, the major portion of the 
free energy of nucleic acid molecules is accounted for by secondary structures (Flamm  et 
al., 2004, Heine et al., 2006, Wolfinger et al., 2004, Wuchty et al., 1998). Thus, the 
predicted secondary structures and associated thermodynamics presented in the current 
study provided a theoretical model of the potential folding patterns of the aptamers that 
confer structural compatibility for target-binding. 
4.5 Optimisation of aptamers through rational truncation 
Aptamer functionality can be improved by the post-SELEX optimisation through the 
truncation of the aptamer sequences to their minimal target-binding motifs (Savory et al., 
2010, Shangguan and Tang Z., 2007, Zhou, 2010). Two candidate aptamers CSIR 2.11 
and CSIR 2.19 were chosen for post-SELEX optimisation in the current study. CSIR 2.11 
was chosen because it was better characterised and showed potential clinical utility when 
















selected based on its lowest dissociation constant value relative to the other aptamers. 
The truncation of aptamers CSIR 2.11 and 2.19 was conducted on the basis of their 
predicted secondary structures. Nucleic acid secondary structures have been widely used 
as a “surrogate for function” (Flamm  et al., 2004, Mathews and Turner, 2006, Nonaka et 
al., 2010, Wolfinger et al., 2004, Wuchty et al., 1998). This notion is further 
demonstrated by in silico selections (Patzel 2004; Hall et al. 2007), and the post-selection 
analyses of aptamer secondary structures (Matthews et al 2008).  
For the two aptamers chosen for truncation in this study, the objective was to remove 
non-essential nucleotides on the aptamer sequences and retain the parts of the sequences 
that are essential for target binding. This would potentially give the aptamers better 
structural stability and consequently improved functionality and specificity (Nonaka et 
al., 2010, Potty, 2008), and reduce their dimensions to make them compatible with 
downstream biosensor design (Zhou, 2010). Moreover, the design of shorter-sequence 
aptamers would not only make them easier to produce on a larger scale, but also more 
cost effective (Shangguan and Tang Z., 2007). To achieve this objective, the regions of 
the aptamer sequences that contribute to target-recognition and binding were deduced 
based on the mfold-predicted MFE structures. Based on the MFE structures, the 
sequences of four truncated derivatives (two per aptamer) were designed. This was done 
by deleting several nucleotides in either direction of the primer regions of full length 
aptamer sequences.  
The folding of the truncated sequences was subsequently simulated, and the truncated 
derivatives retained the secondary structures and free energies of the parent sequences. 
The working hypothesis in this case was that maintaining the overall structure of the 
predicted target-binding region of the aptamer would be essential for retaining the 
functional activity of the truncated versions. The removal of nucleotides from the primer 
sequences of the aptamers did not affect aptamer folding, and would therefore not likely 
















demonstrated through secondary structural analysis of over 2000 aptamers,  that the 
binding of aptamers is not generally enhanced or constrained by constant primer regions 
(Cowperthwaite and Ellington, 2008). 
The current study employed a bioinformatics approach to examine the influence of 
sequence length and secondary structures on aptamer function. The secondary-structure 
guided, rational truncation method utilised in the current study, was shown in previous 
studies to be reliable (Potty, 2008, Shangguan and Tang Z., 2007). The method provided 
a rapid and effective approach through which to shorten the aptamer sequences, and 
eliminated the laborious technical demands that come with the traditional methods such 
as enzymatic footprinting or partial hydrolysis (Bing et al., 2010, Nonaka et al., 2010). 
4.6 Folding energy landscapes of full length and truncated ESAT-6.CFP-10 
aptamers 
Secondary structure prediction methods generally identify functional structures of nucleic 
acid molecules on the basis of thermodynamic equilibrium, without factoring in the 
dynamics of the folding process (Washietl et al., 2012). Therefore, to get a broader 
picture of the folding dynamics of the aptamers used in the current study, and to 
determine whether there would be any notable differences between the full length and 
truncated aptamers in this regard, folding energy landscape analyses were performed 
using the computational methods. 
Thermodynamically, a folding energy landscape provides a visual depiction of how close 
the MFE is to its thermodynamic neighbours and how much energy would be required for 
a molecule to switch between conformations (Wolfinger et al., 2004, Wuchty et al., 
1998). The greater the energy difference (barrier height) between the MFE and its 
thermodynamic neighbours (suboptimal structures), the less likely it is that these 
suboptimal structures will exist—or be reached within a given folding time (Heine et al., 
















kinetics of the folding process. The folding of an aptamer into a target-cognate 
conformation is a time-sensitive process (Flamm et al., 2000, Flamm et al., 2002). 
Folding kinetics would predict how long it would take for the MFE of a particular 
aptamer to reach maximum potential occupancy within a given population of possible 
conformations (Flamm et al., 2000, Slutsky and Mirny, 2004, Wuchty et al., 1998). In 
addition, the folding kinetics gives an indication of whether the folding process is likely 
to be affected by “kinetic traps”, i.e. the molecule would be stuck in alternative 
suboptimal conformations along the path to the MFE (Flamm et al., 2000, Heine et al., 
2006, Wolfinger et al., 2004). 
To answer some of the questions outlined above for CSIR 2.11 and 2.19 and their 
respective truncated versions, energy landscape analyses were conducted by computing 
barrier trees using the Vienna RNA Package B rriers program. The algorithm yielded 
barrier trees of the low energy portion of the folding landscape of the aptamers. The 
program treekin (part of Barriers) was used to compute the folding dynamics of the DNA 
molecules on the basis of a precomputed barrier tree. Using the discrete model of 
secondary structure folding provided by the program, approximate descriptions of the 
folding dynamics of the selected aptamers at logarithmic time-scales were presented. 
These estimations provided a framework within which to predict whether aptamer 
sequences are likely to switch between conformations, and at which time scales (Flamm 
et al., 2000, Heine et al., 2006, Wolfinger et al., 2004).  
For the simulations in this study, based on the nature of the computational tools used 
(Flamm et al., 2000, Heine et al., 2006, Wolfinger et al., 2004), the focus was not on the 
time the system would take to reach a thermodynamically stable equilibrium distribution, 
but rather the refolding time from a selected start structure (representing the denatured, 
open-chain structure) to the ground state global minimum or the MFE. The outcome of 
the computational analyses would give an idea of whether or not the proposed “search 
















(Hermann and Patel, 2000) would occur fast enough for the more thermodynamically 
stable structure (MFE) to be favoured, without the aptamer sequence being trapped into 
some other conformation that does not provide the best affinity for the protein. 
The barriers data for the 90-mer CSIR 2.11 revealed that the MFE reached its maximum 
occupancy later in the folding time scale, and did not turn out to be in the “kinetically 
preferred” subtree with more stable conformations. In addition, the barrier height 
between this subtree and the one containing the MFE is not high, which suggests ease of 
transition between the two basins (Heine et al., 2006). This is also supported by the 
percentage occupancy values on the folding kinetics graphs. The folding kinetics of a 
barrier tree determine whether the molecule has sufficient time to switch into the optimal 
subtree; the one representing a class of more thermodynamically stable structures, or 
whether it will remain trapped in the suboptimal subtree (Heine et al., 2006). Based on 
the data obtained for the 90-mer CSIR 2.11, it is plausible to predict that the suboptimal 
structures represented by local minima 4, 8, and 44 will be present in considerable 
amounts in the structural populations of aptamers leading to the MFE. The data also 
forecast that while the MFE structure of the 90-mer CSIR 2.11 that occurs in solution 
may be fairly stable once formed, the molecules are likely to flip-flop between different 
conformations particularly those in the basin containing local minima 4 and 8. The 70-
mer showed better folding kinetics than the 90-mer and 77-mer, with the MFE being the 
most likely to occur within a biologically reasonable timeframe, and the more 
thermodynamically preferred. 
The 90-mer CSIR 2.19, showed better folding kinetics than did the 90-mer CSIR 2.11 in 
that the subtree that is the most occupied and the more likely kinetically preferred is that 
which contains the MFE. However, the MFE is likely to be strongly challenged by local 
minimum 2. This data corroborates the MFE estimations by mfold, whose output was 
three MFE structures with almost equal ∆G. While this implies a likely conformation 
















time-scale suggests that the MFE will win the challenge and form long before structure 2 
does. The 49-mer CSIR 2.19 aptamer showed similar folding kinetics to that of the 90-
mer, but with a higher MFE population of almost double that of the 90-mer. The 77-mer 
CSIR 2.19 showed better kinetics than that of the 90-mer and 49-mer. Also, the MFE and 
local minimum 2 are found in different basins separated by a high barrier, suggesting that 
a conformational switch is unlikely. 
Overall, there were some notable differences in the folding dynamics between the full 
length and truncated aptamers. The general trend was that the MFE was reached earlier in 
the truncated than in the full length aptamers. These results indicate that the truncated 
aptamers refold into the MFE population faster than the full length aptamers. In addition, 
the MFE’s of the truncated versions had higher population occupancy in comparison to 
those of the full length aptamers. Furthermore, the number of “basins of attraction” 
seemed to decrease in proportion with the sequence length. Taken together, the truncated 
aptamers displayed better folding dynamics than their full length parent sequences. These 
findings support the notion that the p st-SELEX optimisation of aptamer sequences by 
truncation can potentially confer the aptamers with better structural stability (Savory et 
al., 2010, Shangguan and Tang Z., 2007, Zhou, 2010).  
It is however worth noting that the folding kinetics simulations presented herein were 
performed within a designated time-frame in which the folding trajectories do not show 
the rest of the local minima (which along with those represented in the plots will 
collectively add up to a total probability value of 1), and that these “unrepresented 
structures” may dominate the folding pathway and act as “kinetics traps”, preventing the 
sequence from reaching the MFE structure. It is also important to note that the models 
used to predict secondary structures are limited as they do not account for solvation or 
intermolecular influences (Flamm et al., 2000, Slutsky and Mirny, 2004, Wuchty et al., 
1998). Furthermore, the parameters of nucleic acid folding estimated in silico are 
















theoretical models are able to provide useful information about the functional properties 
of nucleic acids, their outputs should not be considered an exact representation of what 
occurs in the natural conditions of the nucleic acid. 
4.7 Functional characterisation of truncated aptamers 
4.7.1 Binding of truncated anti-ESAT-6.CFP-10 aptamers compared to full 
length parent sequences 
From the ELONA, the ability of the truncated derivatives of CSIR 2.11 and CSIR 2.19 to 
recognise target proteins was comparable to that of the full-length parental aptamers. 
There were no significant differences between the binding of each full length aptamer 
and their respective truncated versions. These data demonstrate that all the truncated 
versions of the CSIR 2.11 and CSIR 2.19 aptamers retained the nucleobases, and 
consequently, the structural elements that contribute to the overall target-binding 
conformations of these aptamers. Furthermore, since target-recognition was retained in 
the truncated derivatives, it is reasonable to deduce that the deleted regions do not play a 
crucial role in target-binding.  Additional controls for the ELONA such as an unrelated 
aptamer sequence and protein should be included in future to illustrate the specificity of 
the aptamers (Dupont et al., 2010, Lee et al., 2008). Notwithstanding, the observation that 
the truncated derivatives retained the binding to recombinant protein suggests that they 
are likely to detect TB in clinical samples. 
Furthermore, the ELONA results of the truncated aptamers support the feasibility of 
employing computational secondary structure prediction methods in deducing the target-
binding motifs of aptamers, as well as using this information to optimise the aptamers 
through the elimination of non-essential nucleotides (Nonaka et al., 2010, Rockey et al., 
2011). This “rational truncation” approach (Rockey et al., 2011), can provide a high-
throughput method for optimising aptamer structures for target-recognition (Gao et al., 
2006). While the approach is limited by the reach of the computational tools used, the 
















considered a “surrogate for function” (Cowperthwaite and Ellington, 2008) for nucleic 
acids which adequately depicts aptamer-ligand interactions (Patzel, 2004). 
Since the discovery of aptamers and the description of SELEX over two decades ago, a 
number of methods have been devised through which to exploit and improve the use of 
aptamers. These methods which are aimed at understanding aptamer-target interactions 
include delineating sequence contributions to functions and fittingly truncating sequences 
to shorter derivatives in order to achieve the desired dimensions for specific applications. 
Reduction of aptamer length has been proposed to lead to a population of molecules with 
more stable secondary structures containing a favourable fold that better fit the protein-
binding site (Mallikaratchy et al., 2011, Nonaka et al., 2010, Potty, 2008, Wuchty et al., 
1998). Even though no significant improvement in binding affinity was observed in the 
ELONA evaluations in the current study, the truncated versions are still preferable due to 
the beneficial features described in previous sections. Also, the functional improvement 
of the truncation may have been missed by the ELONA, and could possibly be 
demonstrated in a much more sensitive technique such as SPR (Lee et al., 2008) or 
AuNP-based sensors (Xie and Walton, 2010, Xia et al., 2010). 
All things considered, I propose that the post-SELEX optimisation of the aptamers by 
rational truncation resulted in shorter aptamers that retained the binding functionality of 
the original full length aptamers. Furthermore, truncation of the full length sequences 
resulted in more thermodynamically and kinetically favourable structures as indicated by 
the folding energy landscape data. However, the folding behaviours described by these 
data are theoretical and do not fully represent folding patterns of the aptamers in their 
native environment. Nonetheless, smaller-sized aptamers allow for more desirable 
dimensions and are easier to manipulate in the process of designing different smaller, 
sensitive sensing devices (Zhou, 2010). Further truncations of the anti-ESAT-6.CFP-10 
aptamer sequences may be explored. These can include simultaneous removal of 
















order to generate the shortest possible functional aptamers. Another way of optimising 
selected high affinity aptamers such that they are more structurally stable for downstream 
applications would be to modify the aptamers to have more stabilised base stems, for 
instance by introducing more GC base pairs (cited by (Win et al., 2006). Previous studies 
have reported that sequences lacking strong or stabilised base stems will likely adopt a 
number of potential structures, while the stabilised base stem can significantly reduce this 
population diversity (Win et al., 2006). However, these modifications may only have 
minimal effects on the binding properties of the sequences (Win et al., 2006).  
4.8 Proposed future studies  
Proposed future studies will include testing the truncated aptamers for their ability to 
detect their cognate target in clinical sputum samples, and discriminate between TB and 
non-TB samples. Following this proof-of concept study, the clinical application of the 
truncated aptamers can be examined in a larger sample size as well as a variety of 
biological fluids used in TB diagnosis. Once optimised for detection in clinical samples 
using the ELISA-based method, the truncated aptamers could then be modified 
accordingly and integrated into a simple detection system. For instance, the aptamers 
could be conjugated to gold nanoparticles (AuNPs) to produce a one-step PoC TB 
diagnostic kit (Wang et al., 2008, Xia et al., 2010, Xu et al., 2009). The PoC diagnostic 
kit could be in the format of a simple probe solution (Xia et al., 2010, Xie and Walton, 
2010) or lateral flow device (Liu et al., 2009, Liu et al., 2006), which would allow for the 
rapid, colorimetric detection of MTB antigens such as CFP-10 and ESAT-6. Thus, to 
optimise the design of the system, recombinant ESAT-6.CFP-10 antigens would be used 
as targets of detection, and the sensor could later be tested on a cohort of relevant clinical 
samples. To improve the specificity of the aptamer-based detection system, the anti- 
ESAT-6.CFP-10 aptamers could be used in pairs. Aptamer-pairing will likely multiply 
the specificity of the monoclonal aptamers for the intended analyte in a complex sample 
















being occupied by other proteins in the analyte sample, consequently reducing the noise 


















5.1 Summary of findings  
This work focused on the post-SELEX optimisation and functional analysis of aptamers 
that bind the ESAT-6.CFP-10 MTB antigens, which are putative biomarkers of TB. To 
do this, the intermolecular and intramolecular properties of the aptamers were studied 
using experimental and bio-informatics approaches. The binding properties of the 
aptamers were determined using SPR technology, EMSA and ELONA. SPR was used to 
determine dissociation constants of the aptamer-CFP-10 monomer interactions, while 
EMSA was carried out to interrogate the aptamer-ESAT-6.CFP-10 interaction. Binding 
kinetics of the five aptamers as evaluated by SPR showed tight and concentration 
dependent binding to the target CFP-10 monomer, with dissociation constant values in 
the lower nanomolar ranges. The aptamer that showed the best binding kinetic 
interactions to the CFP-10 target was CSIR 2.19, with a dissociation constant (KD) of 
1.6 nM. The EMSA experiments yielded inconclusive results, and thus dissociation 
constants could not be derived from this data. Structural characterisation of the aptamers 
was performed using mfold and Vienna RNA software packages, to delineate the 
secondary structures and associated folding dynamics.  
Based on the computationally predicted secondary structures, the aptamers were 
rationally truncated to remove non-essential nucleotides which are not involved in 
target-binding. Truncation was carried out for potential optimisation of the aptamers 
with downstream considerations such as improved binding functionality and specificity, 
and cost, prior to conjugating them to reporter systems such as nanoparticles. The post-
SELEX optimisation of the aptamers by rational truncation yielded shorter and lower-
cost molecules which bound to the CFP-10 target protein with affinities comparable to 















predicted by theoretical models when compared to their full length parental sequences. 
These findings confirm that it is feasible to rationally truncate the anti-ESAT-6.CFP-10 
aptamers based on predicted secondary structures, and preserve or improve their binding 
properties. Collectively, these findings suggest that the truncated anti-ESAT-6.CFP-10 
aptamers can be used as candidate probes for the detection of the MTB antigens and 
consequent diagnosis of TB. 
5.2 Conclusions and implications of the work 
This study was undertaken as a part of the process towards developing detection probes 
that could potentially discriminate TB from non-TB samples. The key objectives of this 
study were the characterisation and post-SELEX optimisation of selected anti-ESAT-
6.CFP-10 ssDNA aptamers previously isolated by our research group (Rotherham et al., 
2012).  The results of the current study present the binding kinetics of six anti-ESAT-
6.CFP-10 aptamers, theoretical predictions of the structural contributions of these 
aptamers to their target-recognition function, the feasibility of post-SELEX optimisation 
of aptamers by rational truncation, as well as experimental evidence to support the 
functional performance of the rationally truncated aptamers. The rationally truncated 
aptamers were able to recognise their cognate target in a comparable manner to their full 
length parental counterparts, suggesting that the truncated aptamers will likely be able to 
detect TB in clinical samples. The clinical utility of the resultant optimised aptamers 
will, in future studies outside the scope of this thesis, be tested on TB and non-TB 
clinical samples in a small scale case-controlled clinical study. This will determine the 
potential of the truncated aptamers as candidate probes for use in the design and 
development of affordable; sensitive; specific; user-friendly; rapid; equipment-free and 















APPENDIX A  
 
A.1.1 Kinetics analysis parameters for the full length anti-ESAT-6.CFP-10 
aptamers 
The BIAevaluation-generated parameters used to calculate the kinetics of the full length 
aptamers are shown in Tables 6-1 to 6-5 below.  
Flow cell 
Dissociation 
time (s) kd (1/s) Chi2 
Association  
time (s) ka (1/Ms) kD (M) Chi2 
1 400-600 1.18E-03 0.346 50-120 7.17E+04 1.65E-08 0.0497 
2 400-600 1.02E-03 0.653 50-120 4.29E+04 2.39E-08 0.0426 
3 400-600 9.42E-04 0.936 50-120 3.90E+04 2.41E-08 0.066 
Average   1.05E-03     5.12E+04 2.15E-08   
Standard 





Table A-1: Kinetics analysis parameters for aptamer CSIR2.2 
 
Table A-2: Kinetics analysis parameters for aptamer CSIR2.15  
Flow cell 
Dissociation  
time (s) kd (1/s) Chi2 
Association 
time (s) ka (1/Ms) kD (M) Chi2 
1 400-600 6.26E-04 0.72 50-120 5.09E+04 1.23E-08 1.09 
2 400-600 6.20E-04 0.558 50-120 5.38E+04 1.15E-08 1.14 
3 400-600 6.05E-04 0.561 50-120 4.11E+04 1.47E-08 1.36 
Average   6.17E-04     4.86E+04 1.28E-08   
Standard 
























time (s) kd (1/s) Chi2 
Association 
time (s) ka (1/Ms) kD (M) Chi2 
1 400-800 5.06E-04 0.391 50-120 4.95E+04 
1.02E-
08 1.7 
2 400-800 4.88E-04 0.351 50-120 5.88E-04 
8.30E-
09 0.188 
3 400-800 5.57E-04 0.415 50-120 1.30E+04 
4.93E-
09 0.33 
Average   5.17E-04     2.08E+04 
7.81E-
09   
Standard 
Deviation   
3.5791E-
05     25662.88 
2.67E-
09   
Table A-3: Kinetics  analysis parameters for aptamer CSIR 2.19  
Flow cell 
Dissociation 




time (s)  
ka 
(1/Ms) kD (M) Chi
2
 
1 400-800 2.08E-04 1.04 50-120 2.05E+05 1.02E-09 0.332 
2 400-800 1.88E-04 0.968 50-120 1.18E+05 1.59E-09 0.158 
3 400-800 1.92E-04 0.895 50-120 8.77E+04 2.19E-09 0.18 
Average   1.96E-04     1.37E+05 1.60E-09   
Standard 
Deviation   1.0583E-05     60891.13 5.85E-10   
Flow cell 
Dissociation  
time (s) kd (1/s) Chi2 
Association  
time (s)  
ka 
(1/Ms) kD (M) Chi2 
1 400-800 7.10E-04 0.088 50-120 5.16E+04 1.38E-08 0.18 
2 400-800 5.58E-04 0.112 50-120 5.79E+04 9.64E-09 0.18 
3 400-800 5.31E-04 0.201 50-120 7.52E+04 7.06E-09 0.341 
Average   6.00E-04     6.16E+04 1.02E-08   
Standard 
Deviation   9.65E-05     12219.79 3.4E-09   
Table A-4: Kinetics  analysis parameters for aptamer  CSIR 2.21  


















Figure A-1: Gel-shift analysis of the CSIR 2.11 aptamer. Increasing amounts of protein 
(either CFP-10 or ESAT-6.CFP-10 dimer-indicated above wells) were mixed with 32P-
end labelled CSIR 2.11. Samples were run on a native 8% Polyacrylamide gel. The gels 
were dried and exposed to a phosphor screen and viewed on a phosphorimager. Two 
sets of protein concentrations were studied. A and B are phosphor images from initial 
optimisation assays.  A. More concentrated protein ESAT-6.CFP-10 Dimer (10 µM) 
was used as starting concentration and diluted accordingly. This meant that smaller 
volumes of protein to use. B. a more diluted Dimer1µM was used as starting stock from 
which to make the dilutions, which means slightly larger volumes of protein than in gel 
1, and added extra dimerization buffer (1 final v/v) to make the final binding reaction 
conditions the same those as in gel 1). C and D are representative gels of EMSAs that 
were subsequently performed using the protein dilution protocol in B, at the listed 
























Figure A-2: Binding of CSIR 2.11 to the ESAT-6/CFP-10 dimer and CFP-10 monomer 
assessed by ELONA. Relative binding of the biotin-labelled aptamers to the target 
proteins was measured by streptavidin-HRP-catalysed reactions, detected with TMB 
substrate, and read as absorbance values at 450nm.The bars represent relative binding 
affinity of the full length, 90-mer (black), and the truncated version, 77-mer (grey), of 
the CSIR 2.11 aptamer. The 77-mer bound to the target proteins with affinity values 
comparable to those of the original 90-mer aptamer, and showed significantly higher 


















Figure A-3: Binding of CSIR 2.19 to the ESAT-6/CFP-10 dimer and CFP-10 monomer 
assessed by ELONA. Relative binding of the biotin-labelled aptamers to the target 
proteins was measured by streptavidin-HRP-catalysed reactions, detected with TMB 
substrate, and read as absorbance values at 450nm.The bars represent relative binding 
affinity of the full length, 90-mer (black), and the truncated version,49-mer (grey), of 
the CSIR 2.11 aptamer. The 49-mer bound to the target proteins with affinity values 
comparable to those of the original 90-mer aptamer for both with no statistical 
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